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Abstract 
Introduction
Enhanced Recovery Programmes (ERP) have gained wide acceptance in many 
surgical specialities but there is limited evidence in Liver surgery. A number of 
pilot studies have shown it to be safe but only used historical controls. The 
primary aim of this thesis is to investigate whether an ERP is effective in reducing 
post-operative length of hospital stay. The secondary aims are to investigate the 
differences in time to medical fitness for discharge, morbidity, mortality, pain 
scores, quality of life, patient satisfaction and cost effectiveness when comparing 
an ERP to standard perioperative care for open liver resection surgery.
Methods
This was a single blinded randomised controlled trial (ISRCTN03274575) 
conducted at The Royal Surrey County Hospital NHS Foundation Trust from 
March 2010 till April 2011. A total of 104 consecutive patients were randomised 
in to two groups: the Intervention group (ERP group) or Control group (standard 
therapy group). Group allocation was un-blinded to patients and researchers, but 
to reduce bias both groups were treated by strict protocols, including a standard 
anaesthetic protocol for both groups. The intervention group was treated within a 
full ERP, which included amongst others pre-admission counselling / education, 
pre-operative nutritional supplements, pre-operative carbohydrate loading, goal 
directed fluid therapy for six hours post-operatively, early feeding and 
mobilisation. Primary end point was length of hospital stay. Secondary end points
included time until medically fit for discharge (using strict criteria and a blinded 
assessor), morbidity, mortality, réadmissions, pain control, quality of life (QoL) 
scores using the EQ-5D questionnaire and patient satisfaction. Calculation of 
resources used and direct healthcare costs were calculated over a four week 
period, prospectively from information on operative resources, including theatre 
overhead costs and hospital costs per level of care. Community costs were 
calculated from questionnaires, completed by patients on postoperative days 14 
and 28. The cost and QoL elements were used to perform a cost effectiveness 
analysis.
Results
Ninety-one patients completed the study with the main exclusions being 
inoperability. There were no differences in patient demographics except that 
there were a higher number of patients with the diagnosis of colorectal 
métastasés; and a correspondingly higher number of patients who had 
undergone preoperative chemotherapy in the ERP group. There was also a 
significantly higher P-POSSUM operative severity score in the ERP group. 
Despite undergoing more extensive operations the ERP group reached medical 
fitness for discharge sooner [3.0 versus 6.0 days, p<0.001] and hospital length of 
stay [4.0 versus 7.0 days, p<0.001]. Medical complications were significantly 
reduced [6.5% versus 26.7%, p=0.02], there was no difference in mortality (2.2% 
versus 2.2% (p=0.987), réadmissions (4.4% versus 0%, p=0.495) or pain scores. 
There was an improved quality of life [p=0.02] but no difference in satisfaction 
rates, and a cost saving of £837.25 over the 28 day period.
Discussion
This study demonstrates the efficacy of a specifically designed ERP for 
significantly reducing both the time until being medically fit for discharge and 
hospital length of stay in patients undergoing open liver resection.
The two previous ER in open liver resection studies both showed reduced length 
of hospital stays in the ER group. Lin and colleagues (2011) demonstrated a 
reduction from a median of 11 to 7 days, and the second study by van Dam and 
colleagues (2008) reduced their length of stay from a median of 8 to 6 days. 
However neither of these studies demonstrated any reduction in morbidity. A 
recent pilot study trialling an ERP for laparoscopic liver resection showed a 
median length of stay of 5 days (Stoot 2009) -  one day longer than the median 
length of stay for patients having open surgery in this trial. Moreover we found a 
post-operative stay of only three days was readily achievable with 33% of 
patients in the treatment group leaving hospital on postoperative day three.
In summary this study demonstrated that an ERP is a safe and effective 
intervention for patients undergoing open liver resection surgery. A 
comprehensive enhanced recovery programme with a high compliance to the 
different elements can result in a significant reduction in length of hospital stay 
and fewer postoperative medical complications.
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Introduction
1.1 introduction to major surgery
There is no universally accepted definition of major surgery, but one of the first 
attempts was by the editor of Annals of Surgery in 1917. He stated that major 
surgery was “all work requiring a general anaesthetic, all operations into the 
great cavities, and all operations in the course of which hazards of severe 
haemorrhage” and “all conditions in which the life of the patient is at stake” 
(Pilcher, 1917, page 799). More recent general definitions include any surgery 
involving a risk to the life of the patient or an operation upon an organ within the 
cranium, chest, abdomen or pelvic cavity (Merriam-Webster, 2006). Despite the 
lack of consensus, liver resection surgery which involves a large subcostal 
incision to the abdomen and the risk of major blood loss would be classed as 
major surgery.
Major surgery carries a risk of complication to the patient. Three million surgical 
operations are performed per year in the UK, following which an estimated 
25,000 patients die, giving an overall hospital mortality rate of 0.8 - 1.0% 
(Bennett, 2005; Pearse, 2006). This original estimate has since been disputed; 
the European Surgical Outcomes Study (EuSOS) group conducted a pan- 
European multi-centre cohort study looking at outcomes of consecutive patients 
undergoing non-cardiac surgery over the course of a week (Pearse 2012). During 
this study they found an overall 30-day mortality in the UK of 3.6% (3.2-3.9, 
95%CI). The overall European 30-day mortality rate was 4.0%. The great
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majority of these 25,000 patients (over 80%) have undergone high-risk major 
surgery (Pearse, 2006). Risk of complication can be a result of the surgery itself 
(such as bleeding or wound infection); from the anaesthesia (such as 
hypothermia) or as a result of the physiological changes seen after surgery 
(especially if the patient has a history of chronic conditions e.g. diabetes, heart 
failure, chronic obstructive pulmonary disease and poor nutritional status).
Preventive strategies are adopted to prevent common complications which effect 
mortality. Thromboembolic disease is a frequent and major cause of death after 
surgery; which is attributed to increased platelet aggregation and activation of the 
clotting cascade caused by tissue trauma and exacerbated by perioperative 
immobility. It has been radically reduced by the use of anticoagulants, such as 
low molecular weight heparins. Postoperative pneumonia can result from basal 
atelectasis becoming infected. Atelectasis (the absence of gas from a part of the 
lung) is commonly seen in patients after surgery. It is most frequently seen in 
patients with poor lung function and sputum retention, but also in patients who 
have poorly controlled pain and therefore unable to cough and clear secretions. 
The latter can be reduced by postoperative physiotherapy and effective analgesic 
regimens such as a thoracic epidural (Friese, 2011).
Such complications are not only deleterious to the patient in the short term, 
resulting in an increased hospital length of stay and an increased risk of 
perioperative mortality (i.e. within 30 days of the operation), but they can also 
have a dramatic effect on long-term survival. One study showed that the
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presence of any one of 22 different complications (including pulmonary 
embolism, myocardial infarction and deep wound infection) in a number of 
different major operations reduced median long-term survival by 69% (Khuri, 
2005). This finding has been backed up by a more recent cohort study by 
Moonesinghe and colleagues (Moonesinghe 2014), who demonstrated that 
postoperative morbidity increased the risk of death in both the first twelve months 
and two years after surgery before returning to baseline.
In patients undergoing liver resection for colorectal liver métastasés, the 
presence of postoperative infection (although not wound infection) was an 
independent predictor of disease-free and overall survival (Farid, 2010). This was 
confirmed in another study by Ito and colleagues, who showed that in disease 
states generally associated with a low risk of recurrence, the presence of 
postoperative morbidity significantly affected long-term outcome after hepatic 
resection, decreasing both disease-specific survival and overall disease-free 
survival (Ito, 2008). This shows that any efforts aimed at reducing postoperative 
morbidity is not only likely to improve patient outcomes in the short- term but also 
could influence long-term survival.
After surgery the body undergoes a series of widespread endocrine, metabolic 
and immunological changes. This multi-system response, known as the “stress 
response”, has a number of physiological effects that can, if unchecked, result in 
postoperative morbidity. Circulating catecholamines lead to an increase in 
oxygen demand, which in turn puts strain on different organs, especially the
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heart, and can lead to myocardial ischaemia, myocardial infarction or even 
cardiac arrest.
Attempts have been made to stratify patients’ risk of postoperative complications, 
in particular cardiac complications. This can be used to assess a patient’s 
prognosis after a major operation, to help the clinician and patient to decide 
which treatment is most appropriate for their risk profile, including a less invasive 
procedure. Originally this was done by clinical judgement based on a patient’s 
history, physical examination and select blood results. The first scoring system 
for non-cardiac surgery was introduced by Goldman and colleagues in 1977 
(Goldman et al, 1977); it used a total of nine different clinical variables which 
were all independent risk factors for postoperative cardiac complications. Lee 
and colleagues modified the original Goldman index and introduced a revised 
cardiac risk index in 1999. They used six clinical variables to stratify risk: a 
history of ischaemic heart disease (IHD), cerebrovascular disease, heart failure, 
insulin-dependent diabetes mellitus, impaired renal function and a high-risk type 
of surgery (Lee et al, 1999). The presence of any of these comorbidities scored a 
point, with a score of one point, for example, giving a 0.9% risk of a post­
operative major cardiac event (including myocardial infarction, pulmonary 
oedema, ventricular fibrillation, primary cardiac arrest and complete heart block). 
Two points resulted in a 6.6% risk and three or more points in an estimated 11% 
risk, whilst zero points resulted in a 0.4% risk. Boersma and colleagues 
meanwhile used surgery itself to stratify risk, dividing risk into low, intermediate 
and high risk depending on the possibility of cardiac death after the particular
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grade of surgery (Boersma et al, 2005). Using the Lee Cardiac Risk Index they 
defined <1% risk of cardiac death as low risk, and included breast, dental and 
gynaecological surgery. Intermediate risk (1-5%) included abdominal or carotid 
surgery and high risk (>5%) included aortic and major vascular surgery.
However morbidity is not only cardiovascular in origin; it can also include other 
organs including respiratory failure or pneumonia, paralytic ileus, deep vein 
thrombosis or pulmonary embolism, acute kidney injury or acute confusion.
Other scoring systems also exist to stratify risk, including POSSUM 
(Physiological and Operative Severity Score for the enumeration of Mortality and 
morbidity- Copeland, 1991) and the more updated P-POSSUM (Portsmouth- 
POSSUM -  Prytherch, 1998), which use a combination of physiological and 
surgical scores to predict postoperative morbidity and mortality.
The original POSSUM score was introduced in 1991 but was found to over­
predict the risk of death by a factor of greater than twofold and up to sevenfold in 
the lowest risk group. The P-POSSUM was introduced later to take this over­
prediction of mortality into account. The POSSUM scores have been criticised for 
requiring data that can only be accurately supplied after an operation; for 
example, blood loss, and presence of peritoneal soiling or presence of 
malignancy. The presence of malignancy is important as often the exact tissue 
diagnosis is unknown prior to surgery (just a high index of suspicion). As a tissue 
biopsy can lead to spread of cancer along the path of the needle, these patients 
are usually investigated preoperatively with computerised topography (CT) plus
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positive emission tomography (PET) scans. Therefore the absolute risk can only 
be calculated postoperatively and after tissue diagnoses have been conducted. 
Nevertheless, the scoring system has wide applicability and plays an important 
role in comparative surgical audit.
Major surgery has a large physiological impact on patients, such as pain, 
nausea, insomnia, fatigue and complications such as paralytic ileus or 
pneumonia. The traditional approach to care has used principles such as 
prolonged fasting pre- and post-surgery, extended periods of bed-rest and use of 
bowel preparations for colorectal surgery. However, these may be unnecessary 
and could delay return to preoperative functional levels. In a cost-effective MHS, 
this has further implications for extended hospital stays after major surgical 
operations. Ways of potentially reducing hospital stay will be introduced in 
section 1.3; an Introduction to Enhanced Recovery.
1.2 Introduction to liver resection surgery
The first recorded liver resection was performed in Germany by Carl von 
Langenbuch in 1887 who removed a pedunculated tumour from the left lobe of a 
thirty year old woman (Foster, 1991). Despite major haemorrhage at the time of 
surgery the patient survived.
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In the 1970’s mortality for liver resection surgery was 20% (Stümphe, 2009), and 
was most commonly caused by haemorrhage or liver failure. Advances in 
anaesthetic and surgical practice have led to a significant reduction in 
perioperative mortality risk to 2-3% (Karanjia, 2009; Simmonds, 2006). However, 
morbidity after liver resection surgery remains high, between 15-48% (Parikh, 
2003; Benzoni, 2007; Benoist, 2008; Nordlinger, 2008; Karanjia, 2009). 
Therefore, high quality perioperative multidisciplinary care is essential for patient 
undergoing liver resection surgery.
Lesions requiring resection may be benign (10%) or malignant (90% - Jones, 
2011). Twenty per cent of malignant lesions are primary tumours whilst 80% are 
metastatic. Benign lesions include haemangioma, focal nodular hyperplasia and 
hepatic adenomas. The most common primary liver carcinoma is hepatocellular 
carcinoma which accounts for around 80% of lesions. The second most common 
is cholangiocarcinoma, which usually arises from the bile duct.
By far the most common indication for liver resection surgery is for metastatic 
spread of colorectal cancer. Approximately 32,000 patients present each year in 
the United Kingdom with colorectal cancer and between 20-25% of these 
patients will have liver métastasés (Stümphe, 2009), and up to 50% will develop 
liver métastasés during the course of their disease (Swan, 2011). Liver resection 
in those suitable for surgery (i.e. with no evidence of distant spread) provides the 
best chance of cure. In the UK, 1600 liver resection surgeries are performed
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every year (Garden, 2006), with reported five-year survival rates as high as 46% 
(Karanjia, 2009).
Many of the advancements in liver resection surgery have come from a better 
understanding of liver anatomy. The liver is divided into eight functional 
segments. Matching divisions of the portal vein, hepatic artery and bile duct run 
into each segment; meaning that adjacent segments can be resected without 
disrupting the blood supply to neighbouring ones (see figure 1.1).
Figure 1.1 Anatomy of the liver -  showing the 8 segments
Postoperative mortality can be directly reduced by reducing blood loss (Stümphe, 
2009). During resection of liver parenchyma the main source of blood loss is 
‘back-bleeding’ from valveless hepatic veins. As such it is important to control 
hepatic venous pressure, and therefore central venous pressure (CVP), in order 
to minimise blood loss. Jones et al (1998) reported that if CVP was >6 cm H2O, 
blood loss was around 1000 ml, but was only 200 ml if the CVP was <6 cm H2O.
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Blood transfusions also decreased from 48% to 5% in the same study if the CVP 
was maintained below 6 cm H2O.
Techniques used to maintain a low CVP can include: head-up position (or 
reverse-trendelenburg); avoidance of positive end expiratory pressure (PEEP) 
ventilation; minimal fluid administration; diuretic use (e.g. furosemide); 
vasodilators such as glyceryl trinitrate (GTN) infusions and thoracic epidural use 
which can help reduce systemic vascular resistance and therefore CVP (Redai, 
2004; Stümphie, 2009). However maintaining a low CVP to reduce blood loss 
must be balanced with the potential risk of organ hypoperfusion and the 
uncommon but potentially serious risk of air embolus (0.1% in one study -  Allen, 
2003). Despite these risks, a low CVP technique has been proven to be safe with 
a low-risk of post-operative renal failure (Melendez, 1998; Patel, 2006).
Postoperative liver failure or hepatic insufficiency is one of the more serious 
complications resulting in death after liver resection surgery. The incidence has 
been reported as high as 32% (Hammond, 2011), but is more typically around 
8% overall (Schreckenbach, 2012). Schindl and colleagues suggested that the 
risk should be quoted as less that 1% in patients with no parenchymal disease 
and having small resections; 10% when four segments are being resected and 
30% for those having five or more segments resected (Schindl, 2005).
Postoperative liver failure is the major cause of death after liver resection. 
Between 60 and 100% of deaths after liver resection are estimated to be from
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hepatic insufficiency/failure (McCall, 2001; Balzan, 2005; Schindl, 2005; Sun, 
2005; Mullen, 2007). Insufficiency or failure is characterised by failure of hepatic 
synthetic or excretory functions, which include non-obstructive jaundice 
(hyperbilirubinaemia), fluid retention and coagulopathy (prolonged prothrombin 
time) and possibly hepatic encephalopathy; there is also an increase in 
susceptibility to complications especially sepsis. This may result in protracted 
stays in intensive care and therefore ultimately longer hospital admissions 
(Mullen, 2007).
Despite its potential severity, it is interesting to note that there exists no 
universally accepted definition of postoperative liver failure (Hammond, 2011) 
and therefore it is difficult to accurately determine its incidence. The International 
Study Group of Liver Surgery has recently attempted to address this issue, 
defining it with the following statement (Rahbari, 2011 : pg. 715):
“a postoperative acquired deterioration in the abiiity of the liver to maintain its 
synthetic, excretory and detoxifying functions, which are characterized by an 
increased international normalized ratio and concomitant hyperbilirubinemia on 
or after postoperative day 5”.
The Study Group also differentiated the severity of postoperative liver failure into 
three different grades, from A to C, depending on the level of treatment needed. 
Grade A implies abnormal blood tests but no change in clinical management; 
grade B suggests the degree of liver failure needed clinical management but not
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invasive therapy; whilst grade C acute postoperative liver failure that requires 
invasive treatment (Rahbari, 2011 ).
A common previous definition of postoperative liver dysfunction came from 
Balzan et al (2005) who described the “50-50 criteria” which is based on a serum 
bilirubin concentration above 50 pmol/l and a prothrombin time (PT) less than 
50% of baseline (or INR >1.7) on postoperative day-5. Most of the definitions are 
used to predict mortality, rather than the presence of postoperative liver failure, 
and if the 50-50 criteria are met on postoperative day (POD) the risk of mortality 
is 20% and rises to 59% if they are present on POD-5 (sensitivity 69.6%, 
specificity 98.5%). These results were further validated by a more recent 
retrospective study of over a 1000 patients (Mullen, 2007). The main criticism of 
the 50-50 criteria has been that it can only be applied on day-5 and not earlier, 
when it may be too late to use as a preventative measure.
Another score uses serum lactate and encephalopathy, in addition to bilirubin 
and PT -  see Table 1 (Schindl, 2005). This is a grading score and was used to 
predict the risk of postoperative liver failure from the calculated residual volume. 
Values were used if they were present for two consecutive readings over a forty- 
eight hour period over the postoperative course.
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Table 1.1: Severity of postoperative hepatic dysfunction score. (Schindl 2005)
Points 0 1 2
Total serum bilirubin (pmol/l) <20 21-60 >60
Prothrombin time (seconds above normal) <4 4-6 >6
Serum lactate (mmol/l) <1.5 1.6-3.5 >3.5
Encephalopathy severity grade None 1 and 2 3 and 4
Points score 0= No dysfunction, 1-2 = miid, 3-4 moderate, >4 severe dysfunction
There are several risk factors for postoperative liver failure, with the most 
important being the size of resection (four segments or more) and evidence of 
preoperative liver parenchymal disease (such as cirrhosis, steatosis or 
chemotherapy-induced liver injury; (Mullen, 2005; Hammond, 2011). Other risk 
factors include vascular occlusive techniques, excessive blood loss and 
transfusion, age over sixty-five (the ability of the liver to regenerate decreases 
with age (lakova, 2003)), diabetes mellitus, poor nutritional status and male sex 
(Hammond, 2011). As well as postoperative dysfunction, increased morbidity 
after liver resection is also associated with larger resections (Alferi, 2001 ; 
Erdogan 2009).
The liver is unique in its ability to regenerate, and this means that for a normal 
liver in a patient with no other risk factors, up to 75% of liver can be resected 
(Clavien, 2010). However those with parenchymal diseases, such as cirrhosis, 
require a larger minimum residual volume (approximately 40%) to avoid
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postoperative liver failure (Clavien, 2004). A similar volume has been suggested 
for those patients that have received intensive chemotherapy treatment (>6 
cycles) prior to liver resection surgery (Narita, 2012). This study found that cut-off 
volumes of 44.8%, 43.1% and 37.7% were independent predictors of overall 
morbidity, sepsis and liver failure respectively.
If, however, there is concern over the size of the liver remnant after resection, 
patients can undergo a procedure called portal vein embolization (PVE) prior to 
undergoing the planned resection. Embolising one of the portal veins can induce 
liver hypertrophy of the remnant section (and atrophy on the operative side) to 
prevent post-resection liver failure (Abulkhir, 2008).
Vascular occlusive techniques can include total occlusion (inflow and outflow) or 
total inflow occlusion, which can be used to control intraoperative blood loss. The 
Pringle manoeuvre refers to the total occlusion of inflow, i.e. occlusion of hepatic 
artery and portal vein inflow to the liver. This limits blood supply into the liver with 
the result that bleeding will principally be a result of hepatic venous pressure, 
which itself should be reduced by a low central venous pressure. Occlusion 
induces ischaemia in the liver remnant (Brooks, 2007), and this can lead to a 
hepatic ischaemia -  reperfusion injury and subsequent hepatic dysfunction. This 
process is mediated via the generation of 0 2 -free radicals and endothelial cell 
damage. For this reason Pringle's manoeuvre is now used much less frequently 
(Lordan, 2009) and only for less than forty-five minutes in total during surgery 
(Sugiyama, 2010). Evidence is emerging that use of the Pringle manoeuvre can
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also be associated with shorter survival rates. A retrospective study from Japan 
showed that Pringle times of sixty minutes or greater was an important 
independent predictor of shorter overall postoperative survival (Ishizuka, 2011).
Intraoperative blood loss of greater than 1.0 to 1.2 litres and the need for blood 
transfusion increases the risk of postoperative hepatic insufficiency and sepsis, 
possibly due to the effects of blood transfusion on immunosuppression (Jenson, 
1992; Kooby, 2003). Diabetes mellitus can alter immune response to surgery and 
is associated with an increase in morbidity and mortality after liver resection 
(Little, 2002; Michalopoulos, 2007). Poor nutritional status can affect outcome 
after major cancer surgery (Chen, 2011); it is associated with an altered immune 
response and can reduce regeneration of liver cells possibly secondary to 
disordered mitochondrial function (Fan, 1994; Bozzetti, 2002; Awad, 2009).
Bile leakage is another specific postoperative complication after liver resection. 
The reported incidence varies between 2.6 and 15.6% (Lo, 1998; Jarnagin, 2002; 
Honore, 2009). The presence of a bile leak postoperatively increases the risk of 
other complications such as sepsis, liver failure and therefore also increases 
length of hospital stay (Capussotti, 2006). Nagano et al defined bile leaks into 
four different types (Nagano et al, 2003), which are managed depending on their 
type, which can involve conservative management or more invasive techniques 
such as ERCP (Endoscopic Retrograde Cholangio-Pancreaticogram) with 
sphincterotomy, or surgical exploration. Serous fluid commonly can build up in
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the form of ascites which can be significant in up to 50% of patients. This is 
usually self-limiting but sometimes requires drainage (Redai 2004).
The liver has many important metabolic and synthetic functions. One of them that 
can be affected postoperatively, especially after major resections is clotting factor 
synthesis. Up to 9% of patients can develop a prolonged prothrombin time 
(Matot, 2002). This has particular importance if epidurals are used for 
postoperative pain relief, as epidural catheter removal cannot occur until clotting 
profiles have normalised due to risk of epidural haematoma formation. Removal 
can therefore be delayed by up to seven days (Matot, 2002). Despite this 
concern, epidural use after liver resection surgery is common (Redai, 2004; 
Hendry, 2010; Lin, 2011). Previous work from our own unit at The Royal Surrey 
County Hospital has also confirmed it to be safe (Patel, 2006).
The incidence of liver resection surgery is on the rise as a treatment for certain 
benign and malignant liver lesions. Currently 1600 liver resections are performed 
in the UK per year as part of treatment for colorectal liver métastasés. It is 
estimated though that up to 3600 patients per year could qualify for surgery and 
this figure is likely to increase with improvements in chemotherapy regimens 
(Garden, 2006).
In summary liver resection surgery has improved dramatically over the last two 
decades with significant reduction in mortality rates. Postoperative morbidity 
remains relatively high and requires an excellent multidisciplinary approach to
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minimise complications. New approaches to perioperative care, such as 
enhanced recovery programmes (see Chapter 1.3), could further improve 
postoperative length of stay and may improve current morbidity rates and the 
patient journey.
1.3 Introduction to Enhanced Recovery Programmes
Enhanced recovery programmes (ERR), also known as ‘fast-track’ surgery or 
‘multi-modal approaches’ to surgery, were first introduced in the 1990’s by 
Professor Henrik Kehlet a gastrointestinal surgeon from Denmark (Kehlet, 1997). 
Kehlet realised that despite advances in surgical and anaesthetic techniques 
patients were still suffering significant morbidity and prolonged recovery times. 
He postulated that by understanding and modifying the stress response that 
occurs after surgery, with its subsequent increased oxygen demand to organs, 
patient outcomes may be improved. The stress response refers to the 
phenomenon of widespread changes in organ function that is seen in patients 
after surgery or trauma; it is mediated via immunological, metabolic and 
endocrine pathways (Bessey, 1995; Kehlet, 1997). Whilst there is no single 
technique or drug that can prevent postoperative morbidity, Kehlet postulated 
that a series of interventions or a ‘multi-modal’ approach may lead to a reduction 
in undesirable sequelae following surgery (Kehlet, 1997; Kehlet, 1999). Therefore 
by targeting factors that can prolong recovery (e.g. paralytic ileus) patients 
should have a more straightforward postoperative course and could have a
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reduced length of stay. In one of Kehlet’s first studies on this subject, a small 
case-series of 16 patients underwent open sigmoid-colectomy operations 
together with combined spinal-epidural analgesia, early feeding and mobilisation 
achieved a median length of stay of only two days (Kehlet, 1999).
Since then many trials using enhanced recovery programmes (ERP) have shown 
a beneficial effect in patients undergoing major surgery, mostly colorectal surgery 
(Varadhan 2010). A meta-analysis by Varadhan (2010) and colleagues analysed 
six randomised-controlled trials in colorectal surgery and demonstrated in the 
ERP group a statistically significant 2.5-day reduction in hospital stay. There was 
also an approximately 50% reduction in the post-operative complication rate. 
There was no difference in the mortality or rate of re-admissions to hospital.
There is evidence of success of ERPs in other specialities, including 
gynaecological (Lv, 2010), orthopaedic (Thomas, 2010), vascular (Murphy, 2007) 
and oesophageal surgery (Jiang, 2009); and this has led to the department of 
health leading a major initiative in pushing forward ER nationally via the 
Enhanced Recovery Partnership Programme. However there is limited evidence 
for its efficacy in liver resection surgery. In section 1.4 the evidence for enhanced 
recovery in liver surgery will be reviewed.
Traditionally ERPs in colorectal surgery have used a series of twenty 
perioperative interventions which aim to maintain normal physiological function to 
try and aid patient recovery (Lassen, 2010). In order to get the maximum benefit
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all patients need to follow and strictly adhere to the programmes (Gustafsson, 
2011). Each of these interventions will be briefly described in the following 
section, some being specific to colorectal surgery and others more general and 
can be applied to any surgery. They will be divided into pre-operative, 
intraoperative and post-operative measures and reference will be made to 
whether they are appropriate for liver resection surgery.
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1.3.1 Pre-operative measures
1.3.1.1 Preadmission information and education :
The ERP suggests that patients should be counselled as to exactly what to 
expect before, during and after surgery and their role in the recovery process. 
Specific targets that patients need to achieve in terms of daily dietary and 
mobilisation goals should be discussed with patients. It is important to adequately 
prepare the patient before undergoing an ERP (Lassen, 2010). Counselling the 
patient prior to surgery is an essential part of this; which can lead to a better 
following of protocol / care pathway and can allow early recovery and discharge 
home (Halaszynski, 2004; Blay, 2005; Forster, 2005). Good pre-operative 
education also reduces anxiety (Shuldham, 2001; Hughes, 2002) and even 
postoperative pain scores after laparoscopic cholecystectomy (Blay, 2005).
More recently enhanced recovery “schools” have been introduced in some 
centres. These include “joint schools” for orthopaedics (Ford, 2012) and ones for 
colorectal surgery (Burumdayal, 2011). These are multidisciplinary sessions, with 
input from clinical nurse specialists, physiotherapists and members of the acute 
pain team. Patients attend the session a few weeks before surgery, in addition to 
their routine pre-assessment clinic appointments, and receive detailed 
information about what to expect before and after the operations. Ford et al 
(2012) showed that for elective orthopaedic surgery, in an otherwise 
standardised perioperative system, the introduction of a “school” can directly 
reduce length of stay and improve patient satisfaction.
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1.3.1.2 Preoperative bowel preparation :
ERP protocols suggest that patients having elective bowel resection should not 
receive routine bowel preparation, which can cause dehydration and electrolyte 
disturbances, especially in elderly patients (Holte, 2004). Historically patients 
having liver resection surgery never received bowel preparation so avoiding a 
change in practise in this case.
1.3.1.3 Preoperative fasting and preoperative carbohydrate loading:
ERP protocols discourage unnecessarily prolonged fasting and suggest two 
hours for clear fluids and six hours for solid food. Moreover patients should 
receive carbohydrate loading preoperatively. A preoperative carbohydrate drink 
reduces by up to 50% the catabolic response to surgery and subsequent insulin
resistance (Soop, 2001). Insulin resistance causing hyperglycaemia is an
independent predictor of morbidity and mortality in major surgery in both 
diabetics and non-diabetics (Doenst, 2005; Gandhi, 2005). A recent study 
showed that strict adherence to an enhanced recovery protocol reduced both 
postoperative complications and symptoms that delayed discharge (Gustafsson,
2011). A carbohydrate drink and postoperative intravenous fluid restriction were 
the only independent predictors of early discharge. After undergoing multivariate 
analysis and adjusting for confounders this study showed that a carbohydrate 
drink decreased by 44% postoperative symptoms, including nausea and 
vomiting, pain, diarrhoea and dizziness, that could delay discharge.
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Carbohydrate is a principal source of energy during liver regeneration, and 
preservation of a liver’s glycogen stores increases its ability to tolerate 
perioperative ischaemic damage, for example, after a Pringle manoeuvre 
(Hassanain, 2008; Ciuni, 2011). It is postulated that pre-operative carbohydrate 
may prevent or minimise liver dysfunction after extensive resections (Hassanain,
2008). Combined oral preload with high dose insulin therapy compared to a 
standard insulin sliding scale in a study of 30 patients showed a significant 
reduction of postoperative liver dysfunction and complications (Fisette, 2012). It 
showed a reduction of postoperative hepatocyte apoptosis, possibly due to an 
increase of substrate availability and an altered cytokine secretion profile.
1.3.1.4 A voiding pre-anaesthetic medication :
According to ERP protocols, patients should not receive any long-acting sedative 
medications prior to surgery to avoid any long-term ‘hangover’ effects. If patients 
are too sleepy immediately after surgery this can interfere with their early 
mobilisation and feeding which could increase length of stay. However a recent 
Cochrane review showed that short-acting pre-medications, used to reduce 
anxiety in day surgery, do not prolong recovery or length of stay (Walker, 2009).
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1.3.2 General intra-operative measures:
1.3.2.1 Standardised anaesthetic protocoi:
The anaesthetic should include short-acting agents such remifentanil, to allow a 
faster wake-up time. The Enhanced Recovery After Surgery (ERAS) society 
recommends also the use of epidural analgesia for open surgery. Avoidance of 
intravenous opiates can delay mobilisation, decrease appetite and slow 
gastrointestinal recovery (Bisgaard, 2002). A meta-analysis showed that although 
epidural analgesia did not on its own reduce postoperative length of stay it did 
provide better pain relief and an earlier return of bowel function compared to 
intravenous opiates alone (Marret, 2007). This improved pain relief was also 
seen up to 72 hours postoperatively in the recent Royal College of Anaesthetists 
Third National Audit project, and confirmed in nearly all types of surgery (Cook, 
2009).
Perioperative use of epidurals can block increased sympathetic activity seen in 
response to severe trauma or major surgery and can lead to a reduced incidence 
of perioperative cardiac events (Rodgers, 2000). Further systematic reviews 
have also shown a reduced incidence of postoperative pneumonia and 
thromboembolism (Liu, 2007). As part of the trial reported in this thesis, we have 
followed a standard anaesthetic protocol (Appendix 8), which both groups will 
receive, together with an epidural for postoperative analgesia.
44
1.3.2.2 Antimicrobial prophylaxis:
ERPs recommend that antimicrobial agents should be used to avoid infective 
complications such as wound infections (Song, 1998; Nelson, 2009). 
Prophylactic agents given prior to surgery can reduce the incidence of surgical 
wound infection by at least 75% (Nelson, 2009).
1.3.2.3 Preventing and treating postoperative nausea and vomiting:
Nausea and vomiting can often be more unpleasant for patients than pain (van 
den Bosch, 2006) and reducing these patient outcomes is a key goal of the ERP. 
Patients who are at a higher risk of postoperative nausea and vomiting should 
receive preventative treatment with dexamethasone at the beginning and a 
serotonin receptor antagonist at the end of surgery (Carlisle, 2006). Risk factors 
include female sex, non-smoker and previous history of either motion sickness or 
postoperative nausea and vomiting.
1.3.2.4 Preventing intraoperative hypothermia:
Preservation of normothermia can reduce the incidence of wound infections, 
cardiac complications and coagulation problems (Scott, 2006). A recent 
retrospective review of patients undergoing liver resection surgery for donor 
lobectomy showed over 50% experienced at least one intraoperative 
complication, including 39% who suffered intraoperative hypothermia (Araz,
2012). During surgery all patients as part of this study undergo active warming 
using both forced air warmers and intravenous fluid warmers.
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1.3.2.5 Perioperative fiuid management:
Excessive intravenous fluid should be avoided perioperatively. Excess fluid can 
cause gut oedema, delaying the return of normal gut function and impairing 
wound or anastomotic healing (Gustafsson, 2011). For each additional litre of 
fluid given during the day of operation the risk of postoperative symptoms 
delaying discharge increased by 16% and the risk of complications by 32% 
(Gustafsson, 2011), as well as increasing length of stay by around 24 hours 
(Levy, 2011).
In contrast, too little fluid can result in dehydration, oliguria and complications 
such as renal failure. Targeted fluid therapy or goal-directed fluid therapy (GDFT) 
can be used to optimise intravascular volume and therefore tissue perfusion in 
abdominal surgery. This fluid therapy can be individualised by optimising stroke 
volume and reduces length of stay and postoperative complications in abdominal 
surgery (Wakeling, 2005; Noblett, 2006). A Cochrane systematic review 
compared thirty-one studies using GDFT (with or without vasoactive drugs) and 
demonstrated no overall reduction in mortality (Grocott, 2013). However it did 
show a reduction in number of complications and a reduced hospital length of 
stay (by on average 1.2 days). Recently the OPTIMISE study, which used 
cardiac output guided GDFT and compared it to clinician guided standard 
therapy in high-risk patients undergoing major colorectal surgery, failed to show 
any reduction in mortality or major morbidity in the first thirty days after surgery 
(Pearse 2014). This was a large mutli-centre RCT performed in the UK, and 
whilst there was no overall difference of interest, if you removed the first ten
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patients from each centre (i.e. the learning curve) then it did show a significant 
reduction.
Many of these trials used oesophageal Doppler technology to monitor 
cardiovascular function and a probe in the oesophagus may be difficult to tolerate 
in the ‘awake’ patient (Levy, 2011). Patients in the current trial were awake 
during the period of goal-direction, therefore LiDCOrapid™ was used as the 
method of guiding individualised fluid therapy.
The LiDCOrapid is an uncalibrated system that uses a specific algorithm from 
pulse power analysis of the arterial waveform to calculate stroke volume (SV). 
This is based on the principle that fluctuations of blood pressure about the mean 
are directly proportional to the stroke volume (Rhodes, 2005). Accuracy of the 
system is influenced by several factors, including;
i) Non-linear compliance of the arterial wall.
The uncalibrated systems of stroke volume calculation assume that the 
compliance of the systemic vasculature is constant. However compliance of the 
arterial wall is non-linear; there is decreased compliance when the mean arterial 
pressure is high. Moreover, during anaesthesia, all agents used to lower CVP will 
alter compliance and could make the reading less accurate so that calculated 
stroke volume is a function of mean arterial pressure (Camporota, 2010).
ii) Damping of the transducer system.
The quality of the trace can affect the calculations; if there is damping of the trace 
it can decrease the precision of these monitors.
iii) Reflection of the pulse pressure waveform by the peripheral arteries.
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The pulse pressure seen in a peripheral artery is a mixture of the pressure wave 
from the heart and reflection from the distal arterial tree; therefore the systemic 
vascular resistance can affect the reflection and the resulting wave used for 
analysis.
However in a setting of haemodynamic stability, these monitors can be used for 
early goal-directed therapy or pre-operative optimisation for elective surgery 
(Camporota, 2010). Monitors using the same algorithm have been used 
successfully in a similar intensive care unit setting with self-ventilating patients; 
however they used oxygen delivery index rather than stroke volume optimisation 
as their target value (Pearse, 2005).
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1.3.3 Surgical intraoperative measures:
1.3.3.1 Laparoscopy-assisted surgery:
Short-term outcomes, including discharge from hospital, are improved when 
laparoscopy-assisted colorectal surgery is used (Tjandra, 2006). Postoperative 
length of stay as low as 23 hours after laparoscopic colorectal surgery has been 
recorded with an enhanced recovery programme (Levy, 2009). However, in an 
already established ERP median postoperative length of stay with laparoscopy 
showed no difference when compared to open colorectal surgery (Basse, 2005).
Laparoscopic liver resections are technically challenging and so the majority of 
resections are still performed as an open procedure. However, more recently 
laparoscopy is increasingly being used for some straightforward resections, 
although the effect on longer-term outcome is unknown (Fancellu, 2011). A 
recent case report suggested that laparoscopic liver resections - a 
pneumoperitoneum combined with a low CVP technique can result in paradoxical 
gas embolism and perioperative stroke (Van Gorp, 2011) and this would delay 
recovery.
Of interest, one pilot study from the Enhanced Recovery After Surgery (ERAS) 
group investigated the effect of laparoscopic surgery within an ERP (Stoot,
2009). This was a multi-centre trial using a prospective intervention group and a 
retrospective control using a non-ER programme and showed a two-day 
difference in patient length of stay (seven in the historical control and five in the
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prospective laparoscopic enhanced recovery group). However due to the small 
sample size, the result was not statistically significant.
1.3.3.2 Surgical Incisions:
A Cochrane review comparing midline and transverse incisions suggested that 
for colorectal surgery transverse incisions led to reduced analgesic use and 
pulmonary complications (Brown, 2005). Definitive conclusions were difficult to 
make due to the differences in method of assessment, the variability of data and 
heterogeneity of the study groups. However it seemed that transverse incisions 
were less painful although they did not result in faster recovery times. For liver 
surgery a transverse incision is usually used but can sometimes be extended 
cranially along the mid-line (sometimes called the ‘Mercedes Benz’ incision), to 
gain access to the posteriorly-located hepatic veins and inferior vena cava. This 
larger incision may potentially have deleterious effects on the recovery of 
patients after surgery for example due to increased pain.
1.3.3.3 Nasogastric tubes:
ERPs suggest that nasogastric (NG) tubes should be avoided. A Cochrane 
review (Nelson, 2007) showed that routine placement of NG tubes in colorectal 
surgery increased the likelihood of postoperative fever, atelectasis and 
pneumonia after surgery. It also showed that in patients who did not have NG 
tubes there was an earlier return of bowel function.
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1.3.3.4 Peritoneal drains:
Evidence gained from colorectal surgery shows that routine use of peritoneal 
drainage should be avoided. Meta-analyses have demonstrated no reduction of 
anastomotic leaks and other complications with the routine use of peritoneal 
drains (Karliczek, 2006). Fong et al (1996) conducted a randomised controlled 
trial showing that routine peritoneal drainage was unnecessary after elective liver 
resection; and this was confirmed by a later Cochrane systematic review 
(Gurusamy, 2007). Van Dam et al (2008), Stoot et al (2009) and Lin et al (2011) 
as part of their enhanced recovery programmes all avoided routine drainage of 
the peritoneal cavity.
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1.3.4 Post-operative measures
1.3.4.1 Urinary drainage:
If patients require longer-term catheterisation (4-7 days), supra-pubic 
catheterisation is more acceptable than using urethral catheters (McPhail, 2006). 
However for shorter times the risk of urinary retention is low, so there is minimal 
advantage of supra-pubic over urethral catheterisation in colorectal (or liver) 
surgery (Basse, 2001). Prompt removal of urinary catheters will also aid early 
mobilisation, which is one of the goals of enhanced recovery programmes.
1.3.4.2 Prophyiaxis against thromboembolism:
Prophylaxis should be used to help avoid potentially lethal post-operative 
thromboembolic complications, such as deep vein thrombosis and pulmonary 
embolism (PE). The risk of PE is usually 1-3% but can be as high as 10% for 
liver resection patients (Dondero, 2006). A systematic review from the Cochrane 
database shows a combination of graduated compression stockings and heparin 
is the optimal prophylaxis for patients undergoing colorectal surgery (Willie- 
Jorgensen, 2004). Liver resection patients are also at extra risk of hepatic and 
portal vein thrombosis usually as a result of intraoperative local damage to veins 
(Buc, 2011), and so require prolonged heparin usage after discharge from 
hospital.
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1.3.4.3 Prevention of post-operative iieus:
Postoperative ileus is a major cause of discomfort and delayed discharge after 
abdominal and other major surgery. A mid-thoracic epidural is much better 
compared to intravenous opioid at preventing it (Marret, 2007). Postoperative 
fluid overload is another important cause of gut oedema leading to ileus (Lobo, 
2002). For each additional litre of fluid given on the day of operation, as part of 
an enhanced recovery programme, the risk of postoperative complications was 
increased by 32% (Gustafsson, 2011). Giving patients the correct amount of fluid 
in the perioperative period by the use of goal directed programmes (i.e. to avoid 
overload), showed that gut function returned earlier and suffered less 
postoperative gastrointestinal morbidity (Wakeling, 2005).
1.3.4.4 Postoperative anaigesia:
Whilst there is some disagreement as to what is the optimal postoperative 
analgesia regimen for laparoscopic colorectal surgery (i.e. epidural vs spinal vs 
intravenous opioid - Levy, 2011); epidural analgesia is considered the gold 
standard for open colorectal surgery (Marret, 2007). There are some concerns 
over anastomotic complications after epidural analgesia, but these are not 
relevant concerns after liver resection surgery. As mentioned in section 1.2, there 
is a potential risk of postoperative clotting dysfunction. Therefore clotting profiles 
(e.g. INR) need to be monitored daily to ensure safe removal of the epidural 
catheter. Thoracic epidurals have been safely and routinely used as part of the 
analgesic regime since the unit in which the study was performed started liver 
resection surgery in 1996 (Patel, 2006; Karanjia, 2009).
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IC E R -
QALY^ -QALY,„ QALY
This was the cost utility analysis followed in this study and its outcome was a 
cost per QALY gained.
2.10 Clinical monitoring data:
2.10.1 Epidural management:
The time that the epidural infusion was stopped, and when the catheter was 
removed were recorded. The reason for any non-compliance with the ER 
protocol was also noted.
2.10.2 Bowel function:
Patients were assessed daily as to when bowel sounds first reappeared, the day 
the patient first passed flatus and when the patient first opened their bowels. The 
day when oral and then solid diet was first fully tolerated was also recorded.
2.10.3 Fluids:
Patients in the treatment / ERP group received six hours of goal-directed fluid 
therapy, and the standard / control group’s fluid therapy was managed by the 
ICU team (section 2.5.1). The time taken until first oral fluid and first solid food 
was recorded in minutes. The amount of oral fluid was also recorded in millilitres 
for the first six and 24 hours. The amount of intravenous fluid given was also 
recorded (total as well as crystalloid and colloid quantities), both at six hours and 
24 hours.
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2.10.4 Mobility:
The time when each patient first mobilised was recorded, usually from bed to the 
chair. Mobilising to ‘ward’ was defined as mobilising around the ward but still 
requiring assistance, usually with the physiotherapists. Independently mobile was 
defined as mobilising around unaided. This was also the point at which patients 
were discharged from the physiotherapist service. We recorded the day at which 
patients achieved each mobilisation goal.
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2.11 Statistics analysis
Statistical analysis was undertaken using IBM SPSS versioni 9.0.0.
Continuous data was tested for normality using Kolmogorov-Smirnov and 
Shapiro-Wilk tests. For normally distributed data sets were analysed using 
independent-samples f-tests assuming equality of sample variances.
For asymmetrically distributed data, a non-parametric test such as a Mann- 
Whitney U test was used to compare differences and the null hypothesis was 
rejected at p<0.05.
However as some data sets are skewed, for example length of stay, for continuity 
and clarity all continuous data will be presented as median values with 25% and 
75% Interquartiles [IQRj.
The following datasets were normally distributed: VAS Pain Scores, Body Mass 
Index, EQ5D Health Value Index and VAS Scores, P-POSSUM scores and 
Pringle Clamp times.
Categorical variables were analysed using Chi squared test or Fishers exact test.
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Chapter 3: Results
3.1 Patient and operative details
One hundred and four patients were enrolled into this randomised controlled trial, 
with a total of ninety one patients completing the trial. Thirteen patients were 
withdrawn from the trial after enrolment: nine patients from the standard-control 
group and four from the treatment / ERP group. The major reason for withdrawal 
was because of a change in their oncological status and inoperability at the time 
of surgery (n=5), the rest were reasons such as undergoing laparoscopic surgery 
or for undergoing an additional procedure (see CONSORT diagram, fig 3.1). The 
data were screened and checked for missing values and outliers noted.
Analysis of the data was by intention to treat however for the two patients who 
died, neither reached medical fitness nor discharged home and so these two 
variables were deemed as missing values. But their data (e.g. demographics, 
operative and cost) were included in the analysis.
3.1.1 Demographic factors and histological diagnoses:
The patients’ preoperative demographics from both groups are shown in table 
3.1, there were no significant differences between the two groups. The two 
groups were similar in terms of age, sex and body mass index. There was also 
no difference in terms of ASA and the P-POSSUM physiological scores, 
reflecting the similarity of the two groups in the baseline co-morbidities and 
preoperative physiological status.
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Analysed n=45Analysed n=46
Refused 
consent n=1
Randomised
n=104
Treatment (ERP) 
group 
n=50
Control (Standard) 
group 
n=54
Assessed for eligibility 
N=105
Withdrawn-total: n=4 
Inoperable at time of surgery (n=1 ) 
Inoperable on scan (n=2)
Awaiting surgical date (n=1)
Withdrawn-total: (n=9)
Inoperable at time o f surgery (n=4) 
Inoperable on scan (n=1)
Laparoscopic (n=1)
Additional procedure-splenic wedge (n=1) 
Operation not required (n=2)
Fig 3.1: CONSORT diagram showing the number of patients recruited and their 
distribution into the Treatment and Control groups
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Table 3.1: Patient preoperative demographics between groups.
^Median [IQR] analysed by the Mann-Whitney U test. ^Categorical variables analysed by Chi 
square test
Control Group 
n = 45
ERP Group 
n = 46
p value
Age^ 67 [57-77] 64 [56-70] 0.110'
Sex [M:F] 23:22 31:15 0/M4^
BM|T 25.8 [23.1-29.0] 26.7 [23.4-30.6] 0.329'
ASAI 2 (4.4%) 0 (0%)
0.247^ASA II 38 (84.4%) 43 (93.5%)
ASA III 5(11.1%) 3 (6.5%)
P-POSSUM:
Physiological
score^
16 [14.5-18] 15.5 [14-18] 0.589'
However there were some important preoperative differences between the two 
groups. A statistically higher number of patients in the ERP/ treatment group had 
a diagnosis of colorectal métastasés, 35 versus 26 (p=0.021), and therefore this 
group also had a higher number of patients who had received preoperative 
neoadjuvant chemotherapy (p=0.021), see Table 3.2.
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Table 3.2: Histological diagnosis and preoperative chemotherapy.
^Categorical values analysed by Chi square test
Control Group 
n = 45
ERP Group 
n = 46
Statistical
Significance
Diagnosis:
Colorectal Métastasés (%) 26 (57.8%) 35 (76.1%)
0.021'Métastasés- Other (%) 10 (22.2%) 10(21.7%)
Benign (%) 9 (20.0%) 1 (2.2%)
Neoadjuvant 
Chemotherapy (%)
Yes 25 (55.6%) 36 (78.3%)
0.021’
No 20 (44.4%) 20 (35.6%)
3.1.2 Operative Details
Analysis of the operative details showed a higher number of major resections (> 
3 segments) in the ERP group compared to the standard group, however this did 
not quite achieve statistical significance (p=0.06): see table 3.3. There were no 
differences between the two groups in terms of whether they underwent 
preoperative PVE (p=0.78) or intraoperative Pringle manoeuvre (p=0.34), blood 
loss (z = -0.67; p=0.60) or specimen weights (z = -1.486; p = 0.14). There was a 
significantly higher P-POSSUM operative severity score in the ERP / treatment 
group (p=0.007), which uses blood loss, histological diagnosis and operative 
severity in its calculation. However with the overall P-POSSUM score, although it 
was higher in the ERP group this did not reach statistical significance 33.7 versus 
35.8 (p=0.10). A greater number of patients in the ERP group required blood 
transfusion, seven versus three. Whilst this was not significant (p=0.12), it 
perhaps reflected the higher number of major resections in the ERP group.
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Table 3.3: Operative details in the two groups.
^Median [IQR] analysed by Mann-Whitney U test. ^Categorical variables analysed by Chi square 
test
Control Group ERP Group p value
Major Resection 
(>3 segments)
12(26.7%) 21 (45.6%)
o.oef
Minor Resection 
(<3 segments)
33
(73.3%)
25
(54.3%)
Pre-op PVE 5(11.1%) 6(13%) 0.777''
Intra-op Pringle (%)
8(17.8%) 12(26.1%) 0.33Sf
Pringle Clamp times  ^
minutes 31 [20-40] 20 [16-24.5] 0.09’
Specimen weights  ^g 179.5
[70-606]
373.3
[156-781]
0.137’
Blood loss (ml)^ 341
[150-690]
350
[174-900]
0.596’
P-POSSUM Operative 
severity score^ 17 [13.5-21] 19 [17-21.5] 0.007’
P-POSSUM Overall 
score^ 33 [28-39] 34.5 [31-39.5] 0.095’
Need for blood 
transfusion (%) 3 (7%) 7(15%) 0.118^
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Table 3.4 describes the specific operations that patients underwent divided by 
group. As described in table 3.3 more patients in the ERP group underwent 
major resections (3 or more segments), and this is seen in more detail in table 
3.4. Nine more patients in the ERP group underwent major resections compared 
to the control group (21 vs 12 patients), i.e. there were three more extended right 
hemi-hepatectomies, two more regular hemi-hepatectomies and four more tri- 
segmentectomies. Likewise, eight fewer patients in the ERP group underwent 
more minor resections compared to the control group (25 vs 33), i.e. three fewer 
bi-segmentectomies, one fewer segmentectomy and four fewer wedge 
resections.
Table 3.4: Specific Operations by group
Control Group (%) ERP (%)
Extended Right Hemi- 
hepatectomy
3 (6.7) 6(13.0)
Right Hemi-hepatectomy 6(13.3) 8(17.4)
Left Hemi-hepatectomy 2 (4.4) 2 (4.3)
T ri-segmentectomy 1 (2.2) 5(10.9)
Bi-segmentectomy 13(28.9) 10(21.7)
Segmentectomy 8(17.8) 7(15.2)
Wedge Resection(s) 12 (26.7) 8(17.4)
Total 45 (100) 46(100)
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The definition of an outlier from SPSS is as follows: “An outlier is defined as a 
score that is between 1.5 and 3 box lengths away from the upper or lower edge 
of the box (remember the box represents the middle 50 percent of the scores). 
An extreme score is defined as a score that is greater than 3 box lengths away 
from the upper or lower edge of the box.”
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3.2.2 Secondary end point - time to being medically fit for discharge:
The time to discharge was also significantly shorter in the ERP group compared 
to the control group; 3 [3-4] vs 6 [6-7] days: p<0.001 -  figure 3.3.
Fig 3.3: Time until medically fit for discharge for the control and ERP groups.
standard / Control Group ERP / Treatment Group
GROUP
Median values (line at base of box), interquartile range (box), and range (error bars) not including 
outliers are shown.
o  =  “yellow card” outlier > one and a half box lengths 
*  =  “red card” outlier > three box lengths
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3.3 Clinical outcomes
3.3.1 Morbidity and surgical complications
The median overall morbidity rate was less in the ERP group compared to the 
control group, 17.4% vs 31.1%, but this difference did not reach statistical 
significance (analysed by Chi squared test, p=0.126). The eight patients in the 
ERP group had a total of 14 complications compared to the 14 patients in the 
control group with a total of 28 different complications - see table 3.5.
Liver surgery specific complications (Table 3.6) were also similar in both groups, 
15.2% in the ERP group vs 11.1% in the standard group.
However, comparison of the number of patients with any general medical 
complication revealed significantly fewer in the ERP group (3 vs 12 patients, 
p=0.02, Table 3.7). The total number of complications was also fewer in the ERP 
group: 4 vs 20, p=0.009.
3.3.2 Réadmissions and mortality
There were two réadmissions in the ERP group (both for abdominal collections) 
compared with zero in standard care group but this was not significant (p=0.495) 
- Table 3.8.
There was one death in each group (p=0.987, table 3.8). Both deaths resulted 
from postoperative small liver syndrome in patients who had undergone 
extensive preoperative neoadjuvant chemotherapy.
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Table 3.5: All postoperative complications & morbidity compared between groups 
(a combination of Tables 3.6+3.7)
M orb id ity Control Group ERP Group
Abdom inal Collection/Infection 3 2
Arrhythm ia 3 1
Bile Leak 3 3
Biliary Stricture 0 1
Chest Infection /  Pneumonia 5 1
Delirium 0 1
Gl Bleed 1 0
Hypotension 2 0
Incarcerated port-site hernia 0 1
Perforated diverticulum 1 0
Pleural Effusion 1 0
Postoperative Ileus 3 0
Throm boem bolic disease 1 0
Urinary trac t infection 1 0
Wound Dehiscence/infection 2 0
Transient hepatic insufficiency 1 3
Liver fa ilure 1 1
Total Complications 28 14
No. o f patients w ith  
complications
14 (31.1%) 8 (17.4%)
138
Table 3.6: Liver surgery specific complications between groups
Categorical data analysed with Fishers exact test except  ^Chi square test
Morbidity Control Group ERP Group p-value
Abdominal
Collection/Infection
3 2 0.319
Bile Leak 3 3 0.322
Biliary Stricture 0 1 0.511
Transient hepatic 
insufficiency
1 3 0.266
Liver failure 1 1 0.505
Total complications 8 10 0.829’
Total no of patients 5(11.1%) 7(15.2%) 0.612’
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Table 3.7: General medical complications between groups
Categorical data analysed with Fishers exact test except  ^Chi square test
Morbidity Control Group ERP Group p-value
Arrhythmia 3 1 0.255
Chest Infection / 
Pneumonia
5 1 0.101
Delirium 0 1 0.511
Gl Bleed 1 0 0.5
Hypotension 2 0 0.253
Incarcerated port-site 
hernia
0 1 0.511
Perforated diverticulum 1 0 0.5
Pleural Effusion 1 0 0.5
Postoperative Ileus 3 0 0.129
Thromboembolic disease 1 0 0.5
Urinary tract infection 1 0 0.5
Wound
Dehiscence/infection
2 0 0.253
Total Complications 20 4 0.009^
No. of patients with 
complications
12 (26.7%) 3 (6.5%) 0.020^
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Table 3.8: Morbidity, mortality and readmission rates between the two groups.
^Categorical data analysed with Chi square test except ^Fisher exact test
Control Group ERP Group p-value
Morbidity 14(31.1%) 8(17.4%) 0.126’
Mortality 1(2.2%) 1 (2.2%) 0.987’
Réadmissions 0 (0%) 2 (4.4%) 0.495"
3.3.3 Effect of complications of length of stay and time to discharge.
The presence of a complication has a significant effect on a patient’s hospital 
length of stay and time to medical fitness for discharge. For the control group, 
length of hospital stay was significantly greater with a complication: 8 vs 6 days 
(p <0.001, Table 3.9, total group median 7 days). Likewise, time to medical 
fitness for discharge was significantly greater: 6 vs 7 days (p=0.001, total group 
median 6 days).
Table 3.9: The effect of complications on hospital length of stay and time to 
medical fitness in the Control group
Time to medical fitness, 
days
Length of Stay, days
Total group, n=45 6 [6-7] 7 [6-8]
No Complication, n = 
31
6 [5-7] 6 [5-7]
Complication, n = 14 7 [6.5-9] 8 [7-13]
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For the ERP group length of stay went up threefold from a median of 4 days to 
12 days (p=0.002, Table 3.10). There was no difference in the no-complication 
group and the total group value as the number of complications was small. In a 
similar way, time to medical fitness was significantly greater in the subset with 
complications, compared to the no-complications subset (3 vs 6 days; p=0.001) 
or the total group value.
Table 3.10: The effect of complications on hospital length of stay and time to 
medical fitness in the ERP group
Time to medical fitness, 
days
Length of Stay, days
Total group, n=46 3 [2-4] 4 [3-5]
No Complication, n = 
38
3 [2-4] 4 [3-5]
Complication, n = 8 6 [5-7] 12 [5-13]
The larger increase in length of stay and time to medical fitness with medical 
complications in the ERP group may reflect the greater severity of their 
complications, in particular hepatic insufficiency -  see table 3.6. When direct 
liver-related complications such as hepatic insufficiency or persistent bile leak 
were removed, 12 patients from the control group complications compared to 
only three patients in the ERP group.
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3.3.4 Major and minor surgery and the impact on hospital length of stay
There are substantial differences in the size of liver resection (sections 1.2, 2.6.2) 
and the larger the resection means the greater is the risk of complications, 
especially postoperative hepatic dysfunction or failure. The operative 
demographics show a significantly higher operative severity score and a higher 
proportion of major resections in the ERP group.
Thus, the two groups were individually compared for length of stay and time to 
medical fitness whether patients had a major or minor resection. Length of stay 
remained shorter in the ERP subgroups of major and minor resection when 
compared to respective subgroups in the control arm: minor resections (3.5 vs 6 
days, p=<0.001) and major resections (5 vs 7 days; p=0.004. Table 3.11). In a 
similar way ERP reduced the time to medically fit for discharge compared to the 
control arm for the two subgroups: minor resections (3 vs 6 days, p=<0.001) and 
major resections (4 vs 7 days; p<0.001, Table 3.12).
Table 3.11 : Length of hospital stay for minor and major resections in control and 
ERP groups.
Median [IQR] analysed by Mann-Whitney U test.
Control Group ERP Group p-value
Minor Resection 6 [5.5-8] 3 [3-4] <0.001
Major Resection 7 [6-8] 5 [4-6] 0.004
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Table 3.12: Time to being medically fit for discharge for minor and major 
resections in control and ERP groups.
Median [IQR] analysed by Mann-Whitney U test.
Standard / Control 
Group
ERP / Treatment 
Group
p-value
Minor
Resection
6 [5-7] 3 [2.5-4] <0.001
Major
Resection
7 [6-8] 4 [3-5] <0.001
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3.3.5 Epidural management
There was only one epidural failure, in the control group, who required a 
morphine PCA for pain control.
The majority of patients (93.5%) in the ERP group followed the planned protocol 
of stopping the epidural infusion on postoperative day (POD) 2, and 86.9% had 
their epidurals removed on the same day as per protocol. The patients who did 
not follow this protocol included one patient whose epidural accidently fell out on 
POD-1, and two patients with preoperative chronic pain issues. Four out of the 
six catheters which were not removed on POD-2 as per the ER protocol, were 
due to deranged clotting on routine blood-testing. The remaining two were due to 
chronic pain issues.
The time when epidural infusion was stopped was significantly greater in the 
control group (POD-4 vs POD-2; p<0.001). Similarly the time when the epidural 
catheter was removed was greater in the control group (POD-4 vs POD-2; 
p<0.001. Tables 3.13 and 3.14 show the POD when the epidural was stopped 
and catheter removed in the two groups.
Table 3.13: Postoperative day on which epidural infusion was stopped.
Control Group 
Cumulative %
ERP Group 
Cumulative %
Median POD 4 [3-4] 2 [2-2]
POD 1 1 (2.2%) 1 (2.2%)
POD 2 1 (4.4%) 43 (95.7%)
POD 3 14 (35.5%) 1 (97.9%)
POD 4 25 (91.1%) 1 (100%)
POD 5 4(100%) 0
145
Table 3.14: Postoperative day on which epidural catheter was removed.
Control Group 
(Cumulative %)
ERP Group 
(Cumulative %)
Median POD 4 [3-4] 2 [2-2]
POD-1 1 (2.2%) 1 (2.2%)
POD-2 1 (4.4%) 40 (89.1%)
POD-3 14 (35.5%) 2 (93.4%)
POD-4 25 (91.1%) 1 (95.6%)
POD-5 4(100%) 1 (97.8%)
POD-6 - 1 (100%)
3.3.6 Pain scores
Daily recorded pain scores are shown for the first five postoperative days (Table 
3.15). Scores after this day are not shown as the majority of patients in the ERP 
group had been discharged home, and there was a large amount of missing data 
(e.g. on POD-5 there is 30 data points missing in the ERP group, because they 
were now at home).
The median pain scores on the day of surgery were similar (3 in both groups; 
p=0.509). This was expected as all patients had their epidural managed in 
exactly the same way.
Table 3.15 shows the median daily VAS pain scores. The pain scores were 
broadly similar in both groups across the postoperative course. Of particular
interest is that on POD-3 pain scores were not significantly different (3 [2.3-4.3]
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vs 3 [2-4]; p = 0.195). This is despite the epidural having been stopped and 
removed in the ERP group but was still in place in the control group. A simple 
scatter-plot for these individual pain scores for POD-3 is shown in Fig 3.4 below. 
There was no significant difference in pain scores on either POD-4 or POD-5.
Table 3.15: Median VAS Pain scores in the control and ERP groups POD-0 to 5. 
Median [IQR] analysed by Mann-Whitney U test.
Control Group ERP Group p-value
Day 0 3 [2-4] 3 [2-4.5] 0.509
Day 1 3 [1.5-5] 2.5 [1.5-3.5] 0.112
Day 2 3 [2-4] 3 [2-3.5] 0.064
Day 3 3 [2.3-4.3] 3 [2-4] 0.156
Day 4 3.5 [2-5] 2 [2-4] 0.419
Day 5 3 [2-5] 3 [1.3-4] 0.537
147
Fig 3.4. A simple scatter plot showing each individual patient VAS pain scores on 
POD-3.
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3.3.7 Perioperative Fluids
After six hours postoperative time, the total volume of intravenous fluid given to 
control and ERP groups was similar; 2550 ml in the control group, 2750 ml in the 
ERP group; p=0.071, see Table 3.16. However the volume of colloid comprised a 
larger proportion in the ERP group, 1500 ml, compared with 1000 ml in the 
control group; p<0.001. Correspondingly the control group had significantly more 
crystalloid compared to the ERP; p<0.001. No patients in either group needed 
vasoactive drugs in the first six hours of GDFT.
Table 3.16: Colloid and crystalloid intravenous fluid totals given at six hours 
postoperative time
Median [IQR] analysed by Mann-Whitney U test.
6 hours
Control Group ERP Group p values
Total iv fluids, ml 2550 [2165-3100] 2750 [2500-3250] 0.071
Total colloid, ml 1000 [875-1500] 1500 [1250-2063] <0.001
Total crystalloid, 
ml
1400 [1173-1638] 1000 [1000-1229] <0.001
The 24-hour postoperative fluid volumes infused totals were also similar in the 
two groups; 4630 ml for the control group, 4365 ml - see Table 3.17. As with the 
6-hour totals, the amount of colloid was higher in the ERP group, 2000 ml, 
compared to 1500 ml in the control group; p=0.001. Correspondingly, the control 
group had more crystalloid, 3082 ml compared to the ERP group 2260 ml;
p<0.001.
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Table 3.17: Colloid and crystalloid intravenous fluid totals given in first 24 hours 
postoperatively
Median [IQR] analysed by Mann-Whitney U test.
24 hours Control Group ERP Group p-value
Total iv fluids, ml 4630 [4060-5173] 4365 [3671-5200] 0.487
Total colloid, ml 1500 [1000-2125] 2000 [1500-2563] 0.001
Total crystalloid, ml 3082 [2360-3433] 2260 [1945-2780] <0.001
Intravenous maintenance fluid was stopped significantly sooner in the ERP group 
compared with the standard group; median postoperative day-1 versus day-2 in 
the control group; p<0.001, see Table 3.18.
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Table 3.18: Postoperative day on which intravenous maintenance fluid was 
stopped
Median [IQR] analysed by Mann-Whitney U test.
Control group 
(Cumulative %)
Treatment group 
(Cumulative %)
p-value
Median [IQR] 2 [1-3] 1 [1-1] <0.001
PODO 1 (2.2%) 2 (4.4%)
POD 1 12 (28.9%) 34 (80%)
POD 2 19(71.1%) 8 (97.8%)
POD 3 6 (84.4%) 1 (100%)
POD 4 4 (93.3%) 0
POD 5 1 (95.5%) 0
POD 6 1 (97.7%) 0
POD >7 1 (100%) 0
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3.3.8 Return of bowel function
Although the median time until bowel sounds returned was one day in both 
groups they overall returned significantly sooner in the ERP group; p=0.001, see 
Table 3.19. At day-0 the proportion of patients in the ERP group was significantly 
greater (15.2%) compared to those in the standard group (15.2 vs 4.4%, 
p<0.001). Similarly, at day-1 the proportion in the ERP group was greater than 
control (67.4 vs 46.7%, p<0.001).
Likewise patients in the ERP group passed flatus sooner than the standard 
group, 2 vs 3 days; p=0.018, Table 3.20.
The time for patients to open their bowels was not significantly different in the two 
groups, 4 vs 5 days but this was not statistically significant; p=0.703. Table 3.21. 
However it should be noted however that 19 patients were discharged home 
before their bowels opened in ERP group whilst only seven patients from the 
control group were discharged.
Oral fluid and food was started significantly sooner in the ERP group; 115 vs 330 
minutes for the time to first oral fluids; p<0.001. Table 3.22, and 390 vs 1170 
minutes for time to first solid food; p<0.001. The volume of oral fluid drunk was 
also significantly higher in the ERP group at both 6 and 24 hours: 300 vs 0 ml at 
6-hours; (p<0.001. Table 3.23); 1375 ml vs 810 ml at 24 hours (p<0.001). This 
meant that the intravenous maintenance fluid was stopped on average one day 
sooner in the ERP group; p <0.001, see Table 3.24.
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Oral diet was also started sooner in the ERP group, with the majority of patients 
eating on the evening after surgery compared to the first postoperative day in the 
standard group; p <0.001, Table 3.25.
Table 3.19: Time in days taken until return of bowel sounds. 
Median [IQR] analysed by Mann-Whitney U test.
Standard Group 
Cumulative %
ERP Group 
Cumulative %
Median [lOR] 1 [1-2] 1 [1-1]
PODO 2 (4.4%) 7(15.2%)
POD 1 21 (51.1%) 31 (82.6%)
POD 2 13(80%) 6 (95.6%)
POD 3 8 (97.8%) 1 (97.8%)
POD 4 1 (100%) 0
Missing 0 1
Table 3.20: Time in days taken until passing flatus. 
Median [IQR] analysed by Mann-Whitney U test.
Standard Group 
Cumulative %
ERP Group 
Cumulative %
Median [lOR] 3 [2-4] 2 [2-3]
PODO 0 1 (2.2%)
POD 1 4 (8.9%) 9(21.8%)
POD 2 15 (42.2%) 19(63.1%)
POD 3 14 (73.3%) 13(91.4%)
POD 4 6 (86.6%) 3(97.8%)
POD 5 4 (95.5%) 0
POD 6 1 (97.8%) 0
Missing 1 1
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Table 3.21: Time in days until bowels first opened.
Median [IQR] analysed by Mann-Whitney U test.
Standard Group 
Cumulative %
ERP Group 
Cumulative %
Median [IQR] 5 [4-6] 4 [3-5]
PODO 0 1 (2.2%)
POD 1 2 (4.4%) 1 (4.4%)
POD 2 3(11.1%) 4(13.1%)
POD 3 1 (13.3%) 5 (24%)
POD 4 8(31.1%) 9 (43.6%)
POD 5 8 (48.9%) 6 (56.6%)
POD 6 9 (68.9%) 0
POD 7 3 (75.6%) 1 (58.8%)
POD 8 1 (77.8%) 0
POD>10 3 (84.5%) 0
Missing 7(100%) 18(100%)
Table 3.22: Time to first oral intake in minutes. 
Median [IQR] analysed by Mann-Whitney U test.
Control Group ERP Group p-value
Time to first oral 
fluids, min
330 [210-1355] 115 [88.75-150] <0.001
Time to first solid 
food, min
1170 [987.5 -  
1310]
390 [275-1072.5] <0.001
Table 3.23: Amount of oral fluid (ml) at 6 and 24 hours in both groups. 
Median [IQR] analysed by Mann-Whitney U test.
Control Group ERP Group p-value
Total 6 hours, ml 0 [0-112.5] 300 [178.75-500] <0.001
Total 24 hours, ml 810 [475-1207.5] 1375 [1017.5-1731.3] <0.001
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3.24: Day on which intravenous fluid was stopped.
Median [IQR] analysed by Mann-Whitney U test.
Standard Group 
Cumulative %
ERP Group 
Cumulative %
Median [IQR] 2 [1-3] 1 [1-1]
PODO 0 1 (4.4%)
POD 1 12(28.9%) 34 (80%)
POD 2 19(71.1%) 8 (97.8%)
POD 3 6 (84.4%) 1 (100%)
POD 4 4 (93.3%) -
POD 5 1 (95.6%) -
POD 6 1 (97.8%) -
POD 30 1 (100%) -
Table 3.25: Time until oral diet tolerated 
Median [IQR] analysed by Mann-Whitney U test.
Control Group 
Cumulative %
ERP Group 
Cumulative %
p-value
Median [lOR] 1 [1-1] 0[0-1] <0.001
PODO 2 (4.4%) 26 (56.5%)
POD 1 37 (86.6%) 19(100%)
POD 2 3 (93.3%) 0
POD 3 1 (95.5%) 0
POD 4 2 (100%) 0
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3.3.9 Mobilisation
The ERP group started to mobilise significantly sooner than the control group; p 
= 0.008). The median time to first mobilisation was 1141 minutes for the ERP 
group, compared to 1215 minutes for the control group.
Patients in the ERP group also reached mobilisation goals sooner than the 
control group. 100% of patients in the ERP group had mobilised to chair by 
postoperative day-1, compared to 75.6% of the control group. The median time 
was the same in each group but a greater proportion had achieved this goal by 
day-1; p<0.001 -  Table 3.26.
Table 3.26: Postoperative day on which patients first mobilised to chair. 
Median [IQR] analysed by Mann-Whitney U test.
Control Group 
(Cumulative %)
ERP Group 
(Cumulative %)
p-value
Median [IQR] 1 [1-1.5] 1 [1-1] <0.001
POD-0 - 4 (8.8%)
POD-1 34 (75.6%) 41 (100%)
POD-2 7(91.1%) -
POD-3 3 (97.8%) -
POD-4 1 (100%) -
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Patients in the ERP group mobilised on the ward statistically sooner than the 
control group, with a median average of POD-1 versus POD-3 for the control 
group; p<0.001. Table 3.27. Just over 50% of patients had mobilised on the ward 
on POD-1 compared to none in the control group.
Table3.27: Postoperative day on which patient first mobilised to ward. 
Median [IQR] analysed by Mann-Whitney U test.
Control Group 
(Cumulative %)
ERP Group 
(Cumulative %)
p-value
Median [lOR] 3 [2-4] 1 [1-2] <0.001
POD-0 0 0
POD-1 0 24 (53.3%)
POD-2 16 (35.6%) 15(86.6%)
POD-3 11 (60%) 5 (97.7)
POD-4 9 (80%) 1(100%)
POD-5 4 (88.9%) 0 ,
POD-6 3 (95.6%) 0
POD-8 1 (97.8%) 0
POD-15 1 (100%) 0
Patients in the ERP group mobilised independently on average on POD-3 which 
was significantly sooner than the control group, POD- 5; p<0.001. Table 3.28. In 
fact 82.2% of the ERP group were independently mobile on POD-3 compared to 
only 9.1% of the control group.
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Table 3.28: Postoperative day on which patient became independently mobile 
Median [IQR] analysed by Mann-Whitney U test.
Control Group 
(Cumulative %)
ERP Group 
(Cumulative %)
p-value
Median [IQR] 5 [4-6] 3 [2-3] <0.001
POD-1 0 1 (2.2%)
POD-2 0 12 (29.9%)
POD-3 4(9.1%) 24 (82.2%)
POD-4 9 (29.5%) 3 (88.9%)
POD-5 16(65.9%) 4 (97.8%)
POD-6 8(84.1%) 1 (100%)
POD-7 1 (86.4%) 0
POD-8 3 (93.2%) 0
POD-10 2 (97.7%) 0
POD-48 1 (100%) 0
Surgical drains were used in 80.0% of the control group and in 84.8% of the ERP 
group, these proportions were not significantly different between the two groups; 
p=0.182, Chi square test. The greater absolute proportion in the ERP group may 
reflect the greater number of major resections in this group - see Table 3.3. 
Median time for surgical drain removal was on POD-3 for both groups; p=0.480, 
see Table in Appendix 11.
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Urinary catheters were also removed significantly earlier in the ERP group, with 
median removal on POD-2 compared to POD-5 in the control group; p<0.001, 
see Table in Appendix 11.
Similarly, the central venous line was also removed significantly earlier in the 
ERP group, median time was POD-2 vs POD-3 in the control group; p=0.006. 
Table see Appendix 11.
159
3.4 Quality of Life:
3.4.1 EuroQoi-5D VAS scores
Ninety (98.9% of total patients in the study) completed EQ-5D questionnaires 
were returned from patients in the study. The only missing questionnaire was 
from a patient who developed acute liver failure postoperatively and died on 
POD-3 (ERP group). Data will be presented as median values with 25% and 
75% interquartiles as above as tests of normality (Kolmogorov-Smirnov and 
Shapiro-Wilk) showed that that both the EQ-5D VAS and health value index 
scores were not normally distributed.
The patients’ self-rated health VAS scores were the same in both groups when 
assessed preoperatively, both had the same high median score of 90 on the 0- 
100 scale with 100 being the best imaginable health state; p=0.824. The insult of 
surgery resulted in a marked decrease in VAS scores in both groups (see Fig. 
3.5). The VAS scores in both groups then showed a progressive increase over 
the next 28 days and reached similar values when compared to preoperative 
levels; 81 (p=0.328) and 85 (p=0.663) on POD-28 for control and ERP arms 
respectively. Table 3.29 shows values of POD scores over the 28 days of the 
survey.
On POD-2 patients in both groups had a significant drop in VAS scores
compared with preoperative levels but there was no significant difference
between the groups (60 vs 70 control and ERP respectively, p = 0.137). VAS
scores in the ERP group rose from a median of 70 to 75 on POD-3, whilst the
standard group scores remained at 60, but this difference just failed to reach a
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statistically significant difference (p = 0.052). From POD-3 to 7 there were minor 
recoveries of median VAS in the two groups: from 60 to 70 in the control group 
and from 70 to 75 in the ERP group with the two groups not showing significantly 
different scores at each time point. On POD-10 there was a significantly higher 
median VAS score of 80 in the ERP group compared to one of 70 in the control 
group; p = 0.024). After this time point the scores in both groups continued to 
improve. Although the median scores remained higher in the ERP group they 
never reached statistical significance compared to the control group.
To compare the pattern of VAS scores over the 28-day period the area under the 
curve for each group was calculated (AUC -  see section 2.8.2 for analysis). The 
median area for VAS scores in the ERP group was 2193 [1866 -  2533] 
compared with 2029 [1722 -  2390] in the control group. These values were not 
significantly different; p = 0.084. Overall, the VAS scores in the ERP and control 
were not significantly different over the period of survey.
161
?
I
LU
I
0>
100-
90 -
80 -
70 -
60 -
50 -
40 -  1---
Pre-op
- r
10
Post-operative Day
T "
14 28
G R O U P
I  Standard / Control Group 
I  ERP / Treatment Group
Fig. 3.5: EQ5D-VAS scores for the ERP (green) and control (blue) groups, 
between the pre-operative time and post-operative day 28. Median values with 
25 and 75% interquartiles.
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Table 3.29: Values of EQ-VAS scores for the control and ERP groups at different 
time points.
Median [IQR] analysed by Mann-Whitney U test.
Control Group 
Median [IQR]
ERP Group 
Median [IQR] p-values
Pre-op 90 [70-92] 90 [75-96] 0.824
POD-2 60 [40-73] 70 [49.5-83] 0.137
POD-3 60 [45-78] 75 [55-86] 0.052
POD-5 60 [50-78] 75 [52.5-85] 0.076
POD-7 70 [50-80] 75 [60-89] 0.175
POD-10 70 [55-83] 80 [67.5-90] 0.024
POD-14 75 [60-90] 80 [70-93] 0.082
POD-28 81 [60-90] 85 [73-95] 0.371
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3.4.2 EuroQol-5D Health Value Index scores
The EQ-5D health value index (HVI) scores are made up of five dimensions 
including: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 
Each dimension has 3 levels: no problems, some problems and extreme 
problems. These levels were combined to produce a single summary health 
value index score. These are presented in Fig. 3.6. Similar to the VAS scores, 
the insult of surgery resulted in an immediate decrease in scores showing a 
reduction in quality of life, followed by a gradual increase over the following 28 
days. The scores did also not return to baselines levels by POD 28 (median 
scores of 0.85 vs 0.76 (p=0.059) and 1.00 vs 0.796 (p=0.064) in the control and 
ERP groups respectively).
The initial preoperative HVI scores were similar, with no statistical difference 
between the two groups, (0.85 versus 1.00; p = 0.198). (Note that the 
corresponding preoperative mean scores were 0.83 (SD 0.18) versus 0.86 
(0.16); p=0.251).
In a similar manner as the VAS scores, the HVI scores also dropped significantly 
in the initial period after surgery. However, the scores were reduced less in the 
ERP group when compared with the control group on POD-2 (0.36 vs 0.59; 
p=0.006, control vs ERP). Scores in both groups improved on POD-3 and the 
ERP group remained significantly higher; p=0.001. On POD-5 the scores were 
not significantly different (0.59 versus 0.70, p=0.077). Between POD-7 and POD- 
14 there was a trend to increase in both groups but the ERP values remained 
significantly greater: POD-7, 0.62 vs 0.70; p = 0.008); POD-10, 0.69 vs 0.76; p = 
0.036; and POD-14, 0.76 vs 0.80; p = 0.001). At the final time point (POD-28)
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the two values were not significantly different (0.76 vs 0.79; p = 0.058). The HVI 
scores are shown in Table 3.30.
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Fig 3.6; EQ5D-F1VI scores for the ERP (green) and control (blue) groups, 
between the pre-operative time and post-operative day 28. Median values with 
25 and 75% interquartiles.
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Table 3.30: Values of EQ5D-HVI scores for the control and ERP groups at 
different time points.
Median [IQR] analysed by Mann-Whitney U test.
Control Group 
Median [IQR]
ERP Group 
Median [IQR] p-value
Pre-op 0.848 [0.725-1.00] 1.00 [0.80-1.0] 0.198
POD-2 0.364 [0.08-0.587] 0.587 [0.26-0.76] 0.006
POD-3 0.587 [0.26-0.67] 0.742 [0.59-0.80] 0.001
POD-5 0.587 [0.26-0.69] 0.691 [0.52-0.77] 0.077
POD-7 0.620 [0.44-0.76] 0.700 [0.59-0.80] 0.008
POD-10 0.691 [0.59-0.76] 0.760 [0.66-0.86] 0.036
POD-14 0.760 [0.69-0.76] 0.796 [0.76-0.88] 0.001
POD-28 0.760 [0.69-0.88] 0.796 [0.76-1.00] 0.058
The overall difference in quality of life during this 28-day period was measured by 
the area under the curve (AUC) method. Table 3.31 shows that there was a 
significantly better quality of life in the ERP group; p= 0.002.
This difference in areas can also be extrapolated to give an annualised result or 
Quality Adjusted Life Year (QALY). Table 3.32 shows that there was a significant 
difference in QALY between groups, p=0.002, resulting in an overall QALY gain
of 0.004 for the ERP group. Figure 3.6 This QALY figure places importance on
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time at different health states, for example a year of perfect health would be 
worth a score of one. A score of zero is considered equivalent to death, although 
some health states may be considered worse than death and have negative 
scores
Table 3.31: Area-under-the-curve (AUC) values for the EQ5D-HVI scores in the 
control and ERP groups.
Median [IQR] analysed by Mann-Whitney U test.
Standard Group ERP Group p-value
AUC
35.6
[33.6-37.2]
37.3
[35.5-40.7]
0.002
Table 3.32: Annualised adjusted measure or QALY compared between groups. 
Median [IQR] analysed by Mann-Whitney U test.
Standard Group ERP Group p-value
QALY
0.0980
[0.0920-0.102]
0.1020
[0.0987-0.109]
0.002
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Fig 3.7: Boxplot of the annualised health value index scores between groups.
standard Group ERP Group
GROUP
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3.4.3 EuroQol-SDimension Descriptive System
The EQ-5D descriptive system is made up of five domains each with three levels. 
For each time point each of the different five domains will be compared between 
groups. Preoperatively there was no difference between groups in the number of 
patients reporting problems in any of the different domains that comprise: 
mobility (p=0.200), self-care (p=0.242), their usual activities (p=0.345), 
pain/discomfort (p=0.223) and anxiety/depression (p=0.694) -  see Table 3.33.
On POD-2 patients in the ERP were less likely to report problems with mobility 
(p<0.001) and had fewer problems with self-care (p=0.046). However there were 
no differences in reporting problems in the domains of usual activities (p=0.113), 
pain/discomfort (p=0.223) or anxiety/depression (p=0.566, see Table 3.34).
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Table 3.33: Preoperative values for the five domains of the EQ-5D descriptive 
system.
Categorical data, significance tested with Chi squared test
Control Group ERP Group p-value
Mobility -  
number (%)
No problems 37 (82.2) 42 (91.3)
0.200Some problems 8(17.8) 4 (8.7)
Confined to bed 0 0
Self-care -  
number (%)
No problems 45(100) 43 (93.5)
0.242Some Problems 0 3 (6.5)
Unable to wash/dress 0 0
Usual Activities -  
number (%)
No problems 35 (77.8) 41 (89.1)
0.345Some problems 8(17.8) 4 (8.7)
Unable 2 (4.4) 1 (2.2)
Pain / Discomfort 
-  number (%)
No pain 29 (64.4) 32 (69.6)
0.223Moderate pain 16(35.6) 14 (30.4)
Extreme pain 0 0
Anxiety / 
depression -  
number (%)
Not anxious 28 (62.2) 32 (69.6)
0.694Moderately Anxious 15(33.3) 13(28.3)
Extremely Anxious 2 (4.4) 1 (2.2)
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Table 3.34: The five domains of the EQ-5D descriptive system values at POD-2
for the control and ERR groups.
Categorical data, significance tested with Chi squared test
Control Group ERP Group p-value
Mobility-  
number (%)
No problems 1 (2.2) 19(41.3)
<0.001Some problems 34 (75.6) 21 (45.7)
Confined to bed 10(22.2) 5(10.9)
Self-care -  
number (%)
No problems 10(22.2) 21 (45.7)
0.046Some Problems 30 (66.7) 18(39.1)
Unable to wash/dress 5(11.1) 6(13)
Usual 
Activities -  
number (%)
No problems 3 (6.7) 9(19.6)
0.113Some problems 21 (46.7) 23 (50)
Unable 21 (46.7) 13(28.3)
Pain / 
Discomfort -  
number (%)
No pain 3 (6.7) 8(17.4)
0.223Moderate pain 39 (86.7) 36 (80.0)
Extreme pain 3 (6.7) 1 (2.2)
Anxiety / 
depression -  
number (%)
Not anxious 33 (73.3) 33 (71.7)
0.566Moderately Anxious 11 (24.4) 12(26.1)
Extremely Anxious 1 (2.2) 0
On POD-3 patients in the ERP group were significantly less likely to report 
problems with mobility (p<0.001), self-care (p=0.034) or with usual activities 
(p=0.014). However there were no differences between groups experiencing 
pain/discomfort (p=0.551) or for anxiety/depression (p=0.536) -  see Table 3.35.
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Table 3.35: The five domains of the EQ-5D descriptive system values at POD-3
for the control and ERP groups.
Categorical data, significance tested with Chi squared test
Control Group ERP Group p-value
Mobility -  
number (%)
No problems 8(17.8) 28 (60.9)
<0.001Some problems 32 (71.1) 17(37)
Confined to bed 5(11.1) 0
Self-care — 
number (%)
No problems 16(35.6) 29 (63)
0.034Some Problems 26 (57.8) 15(32.6)
Unable to wash/dress 3(6.7) 1 (2.2)
Usual 
Activities -  
number (%)
No problems 3 (6.7) 12(26.1)
0.014Some problems 28 (62.2) 28 (60.9)
Unable 14(31.1) 5(10.9)
Pain / 
Discomfort -  
number (%)
No pain 3(6.7) 6(13)
0.551Moderate pain 41 (91.1) 38 (82.6)
Extreme pain 1 (2.2) 1 (2.2)
Anxiety / 
depression -  
number (%)
Not Anxious 34 (75.6) 36 (78.3)
0.536Moderately Anxious 11 (24.4) 9(19.6)
Extremely Anxious 0 0
On POD-5 significantly fewer patients in the ERP group reported problems with 
mobility compared to the standard group (p=0.028). There were no other 
significant differences in reporting problems between groups in any of the other 
domains (see Table 3.36 below). On POD-7 and 10 there were no significant 
differences in reported problems between the groups in any of the different 
domains (see Tables 3.37 and 3.38 respectively).
On POD-14 there were significantly fewer patients in the ERP group reporting 
problems with pain when compared to the standard group (p=0.049). There were
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no reported differences in the other domains: mobility (p=0.133), self-care 
(p=0.133), usual-activities (p=0.069) or anxiety (p=0.205, see Table 3.39).
On POD-28 there were significantly more patients in the ERP group reporting no 
problems with performing their usual activities domain in the ERP / treatment 
group (p=0.006) whilst the rest of the domains showed no difference (see Table 
3.40).
Table 3.36: The five domains of the EQ-5D descriptive system values at POD-5 
for the control and ERP groups.
Categorical data, significance tested with Chi squared test
Control
Group
ERP Group p-value
Mobility -  
number (%)
No problems 13(28.9) 25 (54.3)
0.028Some problems 32 (71.1) 19(41.3)
Confined to bed 0 1 (2.2)
Self-care -  
number (%)
No problems 21 (46.7) 25 (54.3)
0.081Some Problems 22 (48.9) 20 (43.5)
Unable to wash/dress 2 (4.4) 1 (2.2)
Usual 
Activities -  
number (%)
No problems 7(15.6) 10(21.7)
0.248Some problems 22 (48.9) 27 (58.7)
Unable 15(33.9) 8(17.4)
Pain / 
Discomfort -  
number (%)
No pain 3 (6.7) 5(10.9)
0.477Moderate pain 39 (86.7) 39 (84.8)
Extreme pain 3 (6.7) 1 (2.2)
Anxiety / 
depression -  
number (%)
Not anxious 34 (75.6) 35 (76.1)
0.720Moderately Anxious 9(20) 9(19.6)
Extremely Anxious 2 (4.4) 1 (2.2)
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Table 3.37: The five domains of the EQ-5D descriptive system values at POD-7
for the control and ERP groups.
Categorical data, significance tested with Chi squared test
Control Group ERP Group p-value
Mobility-  
number (%)
No problems 19(42.2) 26 (56.5)
0.198Some problems 24 (53.3) 19(41.3)
Confined to bed 2 (4.4) 0
Self-care -  
number (%)
No problems 20 (44.4) 26 (56.5)
0.340Some Problems 24 (53.3) 19(41.3)
Unable to wash/dress 1 (2.2) 1 (2.2)
Usual 
Activities -  
number (%)
No problems 6(13.3) 12(26.1)
0.059Some problems 30 (66.7) 31 (67.4)
Unable 9(20) 2 (4.3)
Pain / 
Discomfort -  
number (%)
No pain 3 (6.7) 9(19.6)
0.199Moderate pain 40 (88.9) 35 (76.1)
Extreme pain 2 (4.4) 1 (2.2)
Anxiety / 
depression -  
number (%)
Not anxious 35 (77.8) 36 (78.3)
0.786Moderately Anxious 9(20) 8(17.4)
Extremely Anxious 1 (2.2) 1 (2.2)
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Table 3.38; The five domains of the EQ-5D descriptive system values at POD-10
for the control and ERP groups.
Categorical data, significance tested with Chi squared test
Control Group ERP Group p-value
Mobility -  
number (%)
No problems 24 (53.3) 32 (69.6)
p=0.134Some problems 21 (46.7) 13(28.3)
Confined to bed 0 0
Self-care -  
number (%)
No problems 28 (62.2) 37 (80.4)
p=0.065Some Problems 17(37.8) 8(17.4)
Unable to wash/dress 0 0
Usual 
Activities -  
number (%)
No problems 8(17.8) 12(26.1)
p=0.378Some problems 32 (71.1) 31 (67.4)
Unable 5(11.1) 2 ( 4 j )
Pain / 
Discomfort -  
number (%)
No pain 7(15.6) 11 (23.9)
p=0.350Moderate pain 38 (84.4) 34 (73.9)
Extreme pain 0 1 (2.2)
Anxiety / 
depression -  
number (%)
Not anxious 32 (71.1) 37 (80.4)
p=0.115Moderately Anxiety 13(28.9) 6(13)
Extremely Anxious 0 2 (4.3)
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Table 3.39: The five domains of the EQ-5D descriptive system values at POD-14
for the control and ERP groups.
Categorical data, significance tested with Chi squared test
Control Group ERP Group p-value
Mobility -  
number (%)
No problems 31 (68.9) 38 (82.6)
0.133Some problems 14(31.1) 7(15.2)
Confined to bed 0 1 (2.2)
Self-care -  
number (%)
No problems 35 (77.8) 41 (89.1)
0.133Some Problems 10(22.2) 4 (8.7)
Unable to wash/dress 0 1 (2.2)
Usual 
Activities -  
number (%)
No problems 8(17.8) 19(41.3)
0.069Some problems 35 (77.8) 25 (54.3)
Unable 1 (2.2) 1 (2.2)
Pain / 
Discomfort -  
number (%)
No pain 6(13.3) 15(32.6)
0.049Moderate pain 39 (86.7) 30 (65.2)
Extreme pain 0 1 (2.2)
Anxiety / 
depression -  
number (%)
Not Anxious 34 (75.6) 39 (84.8)
0.205Moderately Anxious 11 (24.4) 5(10.9)
Extremely Anxious 0 1 (2.2)
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Table 3.40: The five domains of the EQ-5D descriptive system values at POD-28
for the control and ERP groups.
Categorical data, significance tested with Chi squared test
Control Group ERP Group p-value
Mobility-  
number (%)
No problems 35 (77.8) 41 (89.1)
0.125Some problems 8(17.8) 3 (6.5)
Confined to bed 2 (4.4) 0
Self-care -  
number (%)
No problems 40 (88.9) 43 (93.5)
0.408Some Problems 4 (8.9) 1 (2.2)
Unable to wash/dress 1 (2.2) 1 (2.2)
Usual 
Activities -  
number (%)
No problems 14(31.1) 30 (65.2)
0.006Some problems 28 (62.2) 13(28.3)
Unable 3 (6.7) 2 (4.3)
Pain / 
Discomfort -  
number (%)
No pain 17(37.8) 16(34.8)
0.595Moderate pain 28 (62.2) 29 (63)
Extreme pain 0 1 (2.2)
Anxiety / 
depression -  
number (%)
Not anxious 34 (75.6) 38 (82.6)
0.350Moderately anxious 11 (24.4) 7(15.2)
Extremely anxious 0 0
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3.4.4 Patient satisfaction
Feedback forms were received back from 96.7% patients. There were three 
forms missing in total: two from the control group and one from the ERP group. 
We asked patients specific questions in relation to patients’ views on the care 
they received during their hospital stay. The first questions relate to the 
preoperative period and the majority of patients in both groups perceived that 
they had received sufficient amount of information at pre-assessment clinic 
(p=0.511). All patients in both groups thought that there was enough opportunity 
to ask questions in the clinic preoperatively (Table 3.41). Thus the pre-operative 
responses were similar in both groups.
Despite the slightly different approaches to pain management, similar numbers of 
patients felt that their pain had been controlled adequately (p=0.673). One 
patient in the ERP group felt that he/she did not start drinking at the correct time 
compared to none in the standard group.
Three patients in the ERP group felt that they did not start to eat at the correct 
time compared to none in the standard group, but this was statistically different 
between groups (p=0.242). However there was no specific feedback as to what 
was wrong with the timing, whether it was too soon or not soon enough.
All patients in both groups felt that they had started to mobilise at the correct time 
with no-one in particular in the ERP group feeling that they started to mobilse too 
soon. One patient in the ERP group felt that they were not discharged at the
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correct time compared with three in the standard group but this difference also 
did not reach statistical significance (p=0.349).
Overall, the structured question revealed no differences between the groups 
regarding their peri-operative care.
Table 3.41 : “Specific questions on perioperative care” 
Significance tested by Fisher’s Exact Test
Control Group ERP Group p-value
Was there enough 
information at pre-admission 
clinic?
Yes 43 44
0.511No 0 1
Missing 2 1
Was there opportunity to ask 
enough questions at pre­
admission clinic?
Yes 43 45
1.00No 0 0
Missing 2 1
Was the pain controlled 
adequately?
Yes 40 43
0.673No 3 2
Missing 2 1
Did you start drinking at the 
correct time?
Yes 43 44
0.511No 0 1
Missing 2 1
Did you start eating at the 
correct time?
Yes 42 42
0.242No 0 3
Missing 3 1
Did you start mobilising at 
the correct time?
Yes 42 44
1.00No 0 0
Missing 3 2
Did you feel that you were 
discharged at the right time?
Yes 39 44
0.349No 3 1
Missing 3 1
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3.5 Economie evaluation
3.5.1 Hospital Costs
All the time values were non-parametric using Kolmogorov-Smirnov and Shapiro- 
Wilk tests and therefore data are presented as median values with 25 and 75% 
interquartile ranges. The resource costs, are presented below with data sources 
are divided into preoperative, operative and postoperative costs.
Additional preoperative costs include the preOp carbohydrate drink which was 
taken the night before and on the morning of surgery, together with the oral 
nutritional supplements taken for three day before surgery (Table 3.42). 
Fully-absorbed postoperative resource costs are presented by different level of 
care and include direct and indirect costs, which were obtained from the hospital 
finance officer - Table 3.44. Direct costs include consumables and salaries (ICU 
consultants, junior doctors, nurses). Indirect costs include auxiliary ICU staff 
salaries (physiotherapists, dieticians), overheads (heating, lighting). Note that in 
our unit it has been found that Level 2 patients cost more than those at Level 3, 
possibly due to some patients requiring more resources e.g. drug expenditure at 
lower level of organ support.
Table 3.42: Rescource Costs -  Preoperative
Item Cost
preOp Carbohydrate Drink £8.40 (for six drinks in total)*
Fortisips Oral Nutritional Supplement £2.94 (for 14 drinks in total)**
"from British National Formulary 
"* Contract price = 14p per bottle
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Operative costs (Table 3.43) included fully-absorbed anaesthetic and surgical 
costs together with the costs of the LiDCOrapid monitor which was used for goal- 
directed fluid therapy in the ERP group.
Table 3.43: Resource Costs - Operative
Item Cost
Anaesthetic £9.16 per minute*
Surgery £15.70 per minute*
LiDCOrapid smartcard £79**
LiDCOrapid Monitor £5930**
LiDCOrapid maintenance contract £577.50 / year (excluding year 
covered by warranty)**
* from Royal Surrey County Hospital finance officer -  ‘Anaesthetic’ includes costs 
of anaesthetists, Operating Department Practitioners and consumables, and 
‘Surgery’ includes cost of theatre staff and all consumables.
** from LiDCO representative
Table 3.44: Resource Costs -  Post-operative
Item Cost*
Level 3 Care £1394.51 /24 hours
Level 2 Care £1652.80/24 hours
Level 1 Care £502.08 / 24 hours
Level 0 Care £151.68/24 hours
from  the critical care group finance officer for the Royal Surrey County Hospital.
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There were no significant differences in anaesthesia between groups when we 
compare median time (p=0.642) or for cost (p=0.695). Likewise there were no 
differences between surgical time (p=0.541), and cost (p=0.573) or for the total 
theatre time (p=0.495) or total theatre costs (p=0.546 - Table 3.45).
Table 3.45: Average theatre times (mins) and cost (£) per groups.
Values presented as median [IQR], with statistical significance tested by Mann-Whitney U
Standard / Control 
Group [IQR]
ERP / Treatment 
Group [IQR]
p-value
Median anaesthetic time 55 [40-60] 52 [45-60] 0.642
Median anaesthetic cost 
[IQR]
£503.8
[366.4-549.6]
£476.32
[412.2-549.6]
0.695
Median surgical time 207 [150-255] 189.5 [163-236.25] 0.541
Median surgical cost 
[IQR]
£3249.9
[2355-4003.5]
£2975.15
[2559.1-3709.13]
0.573
Median total theatre 
time
250 [207.5-312.5] 242 [217.5-280] 0.495
Median total theatre cost 
[IQR]
£3617.6
[2898.05-4507.3]
£3457.35
[3073.375-
4124.57]
0.546
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There was little difference in the median length of level 3 stay when we compare 
between groups with only one patient in each group requiring level 3 care (p= 
0.564), and similarly little difference when we compare level 3 costs (p=0.564). 
Level 2 stays were half a day shorter in the ERP group when compared to the 
standard group, however this was not significant (p= 0.151). For level 2 care 
there was a median £826.40 cost saving in the ERP group however this did not 
reach statistical significance (p=0.181). Level 1 care was also 1 day shorter in the 
ERP group when compared to the standard group but was not statistically 
significant (p=0.075); and similarly there was a median £502.08 cost saving in 
the ERP group but this did not reach statistical significance (p=0.085)
However there was a one day reduction from 3 to 2 days when we compare level 
0 (or normal ward) stays in the ERP group versus standard care (p<0.001). 
Similarly there is a reduction in costs between groups of £151.68 which is exactly 
the cost of a 24hour stay in Level 0 at the Royal Surrey Hospital (p<0.001, see 
Table 3.46 below).
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Table 3.46: Average median number of days spent, and cost, in each level of 
care.
Values presented as median [IQR], significance tested with Mann Whitney U
Control Group 
[IQR]
ERP Group 
[IQR]
p-value
Level 3 
Days
0 [0-0] 0 [0-0] 0.564
Level 3 
Cost (£)
0 [0-0] 0 [0-0] 0.564
Level 2 
Days
2 [1-2] 1.5 [1-2] 0.151
Level 2 
Cost (£)
3305.6
[1652.8-3305.6]
2479.2
[1652.8-3305.6]
0.181
Level 1 
Days
2 [0-3] 1 [0-2] 0.075
Level 1 
Cost (£)
1004.16
[0-1506.24]
502.08
[0-1004.16]
0.085
Level 0 
Days
3 [2-5] 2 [0-2] <0.001
Level 0 
Cost (£)
455.04
[303.36-758.40]
303.36
[0-341.28]
<0.001
185
Additional hospital costs to ERP group;
The first of the additional costs to the ERP group were the Carbohydrate 
preOp™ drinks of which there were 6 in total. The costs were £4.20 per pack of 
3, which gives a total of £8.40 for the preOp™. The Oral Nutritional Supplements 
(Fortisips™) had a contract price for trust of 14 pence per bottle. Therefore for 
three days preoperatively and an average of 4 days length of stay giving the 
average cost of £2.94 for the ONS (3 days preoperatively + average LoS 4 days 
X £0.14 = £2.94).
The LiDCOrapid machine and smart card is one of the more substantial 
additional costs to the ERP group. From personal email correspondence from 
manufacture rep, the fixed costs of the machine was £5930, the maintenance 
contract was £577.5 per year (although not for first year due to warranty). The 
manufactures advise replacement after seven years use, and so the total fixed 
cost over the six years was £3,465. The variable costs of the LiDCOrapid include 
the individual smart card for each patient which costs £79.
Therefore based on an average of 110 patients undergoing liver resection per 
year at the Royal Surrey County Hospital, the average fixed cost per patient was 
£ 12.20 .
(£5,930 + £3,465 / (110x7) = £9395 / 770 = £12.20)
In total the combined fixed and variable costs for the ERP group came to 
£102.54.
(£12.20 + £79 + £8.40 + £2.94 = £102.54)
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Physiotherapy:
From an internal audit by the Physiotherapy Department found that both groups 
received a similar number of physiotherapy sessions postoperatively. On 
average patients in the ER group received 3.9 visits per hospital episode and 
patients in the standard group received 4.3 visits per hospital episode. The 
patients in the ER group had visits two times per day starting on postoperative 
day one, so were usually discharged (from the care of the physiotherapists) at 
the end of postoperative day two. Unlike the standard group who had sessions 
only once a day and therefore on average discharged on post-operative day five. 
Therefore from a cost basis there was no difference between groups, and as the 
indirect costs (such as physiotherapy) was included in the fully absorbed costs 
for each level of care, no more calculations are required.
Pain Team:
This is based on an average 20 minute consultation from a Band 6 specialist pain 
team nurse. Unit cost of a one hour patient contact = £107 (Curtis 2011). 
Therefore a 20 minute consultation would equal £35.67.
Patients are reviewed twice a day by the pain team when they have an epidural 
in-situ, and once removed they have one follow up visit to make sure the patient 
is comfortable. The median time for removal was POD 2 for the ERP group and 
POD 4 for the standard group. With follow up consultations patients in the 
standard group would receive on average four extra visits from the pain nurses, 
which would equal an extra cost of £142.68 per patient. However the costs from
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the financial officer were all fully absorbed costs which would of course include 
the pain team so this is not a true “cost saving”.
Clinical Nurse Specialist:
An additional element of the ERP was the pre-op education, counselling and 
giving the patient daily goals. Whilst during the trial was performed by myself or 
the other researcher (LK), this would be performed by the hepatobiliary clinical 
nurse specialist. However she used to perform a similar role in the pre­
assessment clinic, but the important difference is that she did not give the 
additional information about the ER principles or give the patients daily 
mobilisation and nutritional goals. Since the end of the trial she has tailored her 
talk to include these and give the patients their ER diaries and checklist. She has 
timed these talks and they take the same length of time as they had done before 
(roughly 30 minutes), and so I have deemed that this is not an additional cost.
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When we compare the overall hospital costs between groups then we find a 
significant difference when we just compare the cost of bed days (£653.76, 
p=0.012). And when we add in the cost of the operation and the additional cost 
mentioned earlier then we find a median cost saving of £864.10 in favour of the 
ERP group (p=0.007; Table 3.47).
Table 3.47: Comparison of overall hospital costs between groups 
Values presented as median [IQR], significance tested with Mann Whitney U
Control Group 
median [IQR]
ERP Group 
median [IQR]
p-value
Overall cost per 
bed days
£4262.72
[3211.36-5742.88]
£3608.96
[2420.32-4347.68
0.012
Average total 
hospital costs
£7689.84
[6879.87-9762.82]
£6825.74
[5803.82-8124.08]
0.007
Total group 
hospital costs
£457,622.90 £344,147.10
Difference = 
£113,475.80
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3.5.2 Community Care Usage and Costs
There were a total of 6 missing questionnaires for the first period (from discharge 
to post-operative day POD-14), 4 from the standard group and 2 from the ERP 
group. All four from the standard group and one from the ERP group were still in 
hospital and the remaining patient in the ERP group had unfortunately passed 
away whilst still an in-patient. The data recorded were 'count' data, this was 
changed to a categorical yes / no as to whether or not they had used that 
particular community health service, and therefore able to perform a Chi-square 
test or Fisher’s exact test to detect significance.
From discharge to POD-14: After discharge from hospital until POD 14
despite returning home sooner 11 patients required a visit to their GP surgery 
compared with 18 patients from the standard group, although this did not quite 
reach statistical significance (p=0.066, see Table 3.48 below). No patient in the 
ERP group required a home visit after discharge until POD-14 compared with 
one patient in the standard group and this was not statistically significant 
(p=0.488, see Table 3.49 below).
20 patients from the ERP group required treatment from a nurse at their GP 
surgery compared with 27 from the standard group, although this did not quite 
reach statistical significance (p=0.059, see Table 3.50). There was also no 
difference in numbers of patients requiring a nurse home visit, with 15 patients 
requiring a home visit compared to 13 in the standard group (p=0.815, see Table 
3.51 below).
Statistically there was no difference between groups in those who had hospital 
out-patient appointments; with 4 patients in the ERP group compared with 7
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patients in the standard group requiring appointments (p=0.5235, see Table 
3.52). Two patients in the ERP group required attendance to A&E or walk-in 
clinic compared to none in the standard group which was not statistically 
significant (p=0.496, see Table 3.53).
No patients in either group required visits from social service staff (p=1.000, 
Table 3.54).
No patients in the ERP / treatment group required day treatment (i.e. no 
overnight stay) compared with two patients in the standard group which was not 
statistically significant (p=0.241. Table 3.55). There was also no difference 
between the two groups in number of patients requiring overnight in-hospital 
treatment with one in each group (p=1.00. Table 3.56). There was no difference 
between groups in terms of number of patients needing additional medications, 9 
patients in the ERP group compared with 11 in the standard group (p=0.489. 
Table 3.57). No patients in either group required help at home from social service 
care staff (p=1.00. Table 3.58). But importantly 23 patients in the ERP / 
Treatment group required help from friends and relatives at home compared to 
30 in the standard group, which did reach statistical significance (p=0.047. Table 
3.59).
From POD-14 to POD-28: The questionnaire was repeated 14 days later on 
POD 28, again the count data was changed into a categorical yes / no as to 
whether or not a service was used in order to perform statistical analysis. At POD 
28 statistically significantly fewer patients required visits to their GP surgery in 
the ERP group when compared to the standard group (4 versus 15, p=0.002, see 
Table 3.48).
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Statistically there was no significant difference between groups in their need for a 
GP home visit (0 versus 1, p=0.489, Table 3.49) and the need to see a nurse 
either at the GP surgery (7 versus 10, p=0.435. Table 3.50) or a home visit (9 
versus 8, p=0.911, Table 3.51 ).
No patients in either group required a visit to A&E or walk-in clinic nor required a 
visit from social service staff from the period from POD 14 to 28 (p=1.00). Three 
patients in the standard group required day-stay hospital treatment versus zero in 
the ERP group but this did not reach statistical significance (Table 3.55, 
p=0.242). There were a total of four patients in the ERP group who had overnight 
stays in hospital compared to none in the standard group (p=0.026. Table 3.56). 
Two of these were the réadmissions that occurred in the ERP group. The other 
two were patients who both lived alone and were HIV positive and stayed for one 
and two nights respectively in a charitable HIV convalescence unit.
There were no statistical differences between groups for patients needing 
additional medications (Table 3.57, p=0.398) or for patients needing home help 
from social services (Table 3.58, p=0.489). 22 patients in the standard group 
needed help from friends and relatives at home compared to only 13 in the ERP 
group, however this did not quite reach statistical significance (Table 3.59, 
p=0.071).
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Table 3.48: Number of patients visiting GP surgery (and number of visits
required) Statistical significance when comparing groups from discharge to POD 14
p=0.066, and POD 14-28 -  p=0.002 (Chi square test).
Visit your 
GP
Control Group ERP Group
Discharge to 
POD 14 POD 14-28
Discharge to 
POD 14
POD
14-28
Nil 23 27 33 41
Once 16 12 11 4
Twice 2 2 0 0
Three times 0 1 0 0
Missing 4 3 2 1
Table 3.49: Number of patients who had home visit from GP (and number of 
visits required) - Statistical significance when comparing groups from discharge to POD 
14- p=0.48S, and POD 14 to 28 -  p=0.489 (Fisher’s exact test)
Home visit 
from GP
Control Group ERP Group
Discharge to 
POD 14 POD 14-28
Discharge to 
POD 14 POD 14-28
Nil 40 41 44 45
Once 0 1 0 0
Twice 1 0 0 0
Missing 4 3 2 1
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Table 3.50: Number of patients visiting Nurse at GP surgery from discharge to 
POD 14 (and number of visits required) - Statistical significance when comparing 
groups from discharge to POD 14- p=0.059, and POD 14 to 28- p=0.435 (Chi square 
test)
Nurse at GP 
Surgery
Control Group ERP Group
Discharge to 
POD 14 POD 14-28
Discharge to 
POD 14 POD 14-28
Nil 14 32 24 38
Once 24 7 16 5
Twice 2 1 4 2
Three times 0 2 0 0
Five times 1 0 0 0
Missing 4 3 2 1
Table 3.51 : Number of patients receiving home visit from Nurse (and number of 
visits required) - Statistical significance when comparing groups from discharge to POD 
14- p=0.815, and POD 14 to 28- p=0.911 (Chi square test)
Home visit 
from Nurse
Control Group ERP Group
Discharge to 
POD 14 POD 14-28
Discharge to 
POD 14 POD 14-28
Nil 28 34 29 36
Once 9 2 7 2
Twice 1 3 7 6
Three times 0 0 1 1
Five times 3 3 0 0
Missing 4 3 2 1
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Table 3.52: Number of patients having hospital out-patient appointments (and
number of appointments) - Statistical significance when comparing groups from
discharge to POD 14 -  p=0.523, and POD 14 to 28 -  p=1.000 (Fisher’s exact test)
Hospital Out­
patient
Control Group ERP Group
Discharge to 
POD 14 POD 14-28
Discharge to 
POD 14 POD 14-28
Nil 34 37 41 42
Once 5 1 4 2
Twice 2 0 0 0
Missing 3 4 1 2
Table 3.53: Number of patients visiting A&E or walk-in clinic - Statistical 
significance when comparing groups from discharge to POD 14- p=0.496, and POD 14- 
28: p=1.00 (Fisher’s Exact test)
A+E or Walk 
in
Control Group ERP Group
Discharge to 
POD 14 POD 14-28
Discharge to 
POD 14 POD 14-28
Nil 41 42 42 45
Once 0 0 2 0
Missing 4 3 2 1
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Table 3.54: Number of patients visited by social service staff - Statistical 
significance when comparing groups from discharge to POD 14- p=1.000, and POD 14- 
28: p=1.000 (Fisher’s Exact test)
Social
Services
Control Group ERP Group
Discharge to 
POD 14 POD 14-28
Discharge to 
POD 14 POD 14-28
Nil 41 42 44 44
Missing 4 3 2 1
Table 3.55: Number of patients who had day treatment at hospital (no overnight 
stay) Statistical significance when comparing groups from discharge to POD 14- 
p=0.241, and POD 14 to 28 - p=0.242 (Fisher’s exact test).
Day treatment 
at hospital
Control Group ERP Group
Discharge to 
POD 14 POD 14-28
Discharge to 
POD 14 POD 14-28
Nil 39 39 44 45
Once 2 3 0 0
Missing 4 3 2 1
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Table 3.56: Number of patients needing overnight stays (and number of nights) 
Statistical significance when comparing groups from discharge to POD 14- p=1.000, 
and POD 14 to 28 -  p=0.121 (Fisher’s exact test).
Stay Overnight 
in Hospital
Control Group ERP Group
Discharge to 
POD 14 POD 14-28
Discharge to 
POD 14 POD 14-28
Nil 40 42 43 41
One night 1 0 0 1
Two nights 0 0 1 2
Five nights 0 0 0 1
Missing 4 3 2 1
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Table 3.57: Number of patients who required additional medications from
discharge to POD-28 - Statistical significance when comparing groups from discharge
to POD 14 -  p=0.489, and POD 14 to 28 -  p=0.398 (Chi square test)
Bought or 
received 
medications
Control Group ERP Group
Discharge to 
POD 14 POD 14-28
Discharge to 
POD 14 POD 14-28
Nil 30 38 35 38
Once 7 2 7 4
Twice 3 1 2 3
Three times 1 0 0 0
Five times 0 1 0 0
Missing 4 3 2 1
Table 3.58: Number of patients who required help at home from social service 
care staff - Statistical significance when comparing groups from discharge to POD-14 -  
p=1.000 and POD 14 to 28 - p=0.489 (Fisher’s exact test)
Help from 
Social Care 
(Days)
Control Group ERP Group
Discharge to 
POD 14 POD 14-28
Discharge to 
POD 14 POD 14-28
Nil 41 41 44 45
Once 0 1 0 0
Missing 4 3 2 1
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Table 3.59: Number of patients requiring help at home from friends / relatives
(and how many days) - Statistical significance when comparing groups from discharge
to POD 14 -  p=0.047, and POD 14 to 28 -  p-0.071 (Chi square test).
Help from 
relatives / 
friends (Days)
Control Group ERP Group
Discharge - 
POD 14
POD
14-28
Discharge - 
POD 14
POD
14-28
Nil 11 23 21 33
Once 1 1 1 0
Twice 4 8 3 5
Three times 7 2 5 2
Four times 2 1 1 0
Five times 14 5 13 5
Seven times 2 2 0 0
Missing 4 3 2 1
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Community charges were calculated at the individual patient level per recorded
use of the different NHS items (see table 3.60 below). Overnight hospital charges
(i.e. réadmissions) however were included as part of the hospital charges.
Despite being discharged on average three days earlier, there was no significant 
difference in median community costs between the groups (p=0.486, Table 3.61).
Table 3.60: Resource Costs -  Community
Item Cost
GP consultation £30 per average 11.7 minute consultation*
Home visit from GP £99 inc travel*
Nurse appointment @ GP 
surgery
£43 per hour of face to face contact est. 30 min 
consultation = £21.50*
Home visit from Nurse £73/hr inc travel*
Hospital out-patient appt £100*
A&E / Walk-in clinic £54*
Day Treatment -  (Portal Vein 
Embolisation)
£931**
Social Care £128 per 4 hour*
Medication Not enough detail was provided in 
questionnaires to provide costings
Help from friends/relatives No actual cost to NHS
*From Unit Costs of Health and Social Care 2011- Compiled by Lesley Curtis 
** National Schedule of Reference Costs Year : '2009-10'
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Table 3.61: Total Community costs
Control Group 
median + [IQR]
ERP Group 
median + [IQR]
p-value
Median cost [IQR]
£73
[47.25-203]
£90.25
[21.50-155.50]
0.486
Summative cost £9265 £6723 Difference = £2,542
Table 3.62: Total median costs compared between groups
Control Group 
median + [IQR]
ERP Group 
median + [IQR]
p-value*
Median hospital 
costs
£7689.84
[6879.87-9762.82]
£6825.74
[5803.82-8124.08]
0.007
Median 28 day 
care costs [IQR]
£7864.32
[7326.07-10336.24]
£7027.07
[6105.00-8271.35]
0.011
Total 28 day 
costs
£466,889.30 £355,521.70
Difference = 
£111,367.60
201
A Median Hospital costs = Hospital Costs e r p  Group -  Hospital Costs standard Group 
= -£864.10
When these community costs are added to the total hospital costs then there is a 
significant cost saving of £837.25 (p=0.011) in favour of the ERP group, as seen 
below and in Table 3.62.
A Median Total 28 day care costs = Total Care Costs e r p  Group -  Total Care Costs 
standard Group ”  " £837.25
When this A cost is then divided by the A quality of life measured above, we can 
calculate the Incremental Cost Effectiveness Ratio (ICER)
ICER = A Median Total 28 day care costs / A QALY
ICER = - £837.25 / 0.00446 = - £187,724.22
This result is considerably less than the £30,000 threshold that the National 
Institute for Health and Clinical Excellence (NICE) have set for the NHS, and with 
cost savings and improved quality of life, it would place this programme in the 
‘accept’ part of the cost-effectiveness plane (see Figure 3.8).
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Figure 3.8: Cost-effectiveness plane showing the cost saving and improved 
QALY
-  QALYs
A ccept
+  Cost
A ccept
— Cost
+ QALYs
A ccept
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Chapter 4 Discussion
Between March 2011 and May 2012 a total of one hundred and four consecutive 
patients were recruited and randomised for this study. Thirteen patients were 
withdrawn after randomisation, nine from the control group and four from the 
ERP group. Eight of these cases were due to a surgical decision of inoperability, 
either at the time of surgery or beforehand based on CT or MRI scan images. 
This resulted in a total of forty-five patients in the control group and forty-six in 
the ERP group. Due to a number of cancellations of operations and subsequent 
withdrawals towards the end of the trial, and to ensure the required number was 
reached, one extra was recruited into each group. Together with the 
reinstatement of a patient randomised to ERP group who’s operation had 
previously been cancelled (due to a positive response to chemotherapy), resulted 
in one extra in the treatment group, compared to the planned forty-five achieved 
in the control group.
The number of post-randomisation withdrawals was fairly high and might be a 
potential source of bias. These were due to the fact patients were randomised in 
the pre-assessment clinic early on in the patient journey. The majority of patients 
had a diagnosis of cancer and were referred for surgery by a Multidisciplinary 
Meeting. Once a provisional decision had been made for surgery then a patient 
would be booked for various out-patient appointments needed prior to the 
operation. On occasion a patient would require repeat staging scans which might 
occur after the pre-assessment clinic and therefore after randomisation. If 
disease had progressed too far, then surgery was not performed resulting in a 
post-randomisation withdrawal from the study. With one patient chemotherapy
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had worked so well that an operation was not required resulting in a post­
randomisation withdrawal from the study. Whilst the operating surgeons were not 
blinded, they were unaware of the group to which any patient was allocated until 
they underwent surgery.
4.1 Pre-operative Demographics;
There was no difference between the groups in age, sex, BMI, ASA grade and P- 
POSSUM physiological score, so that the two groups were similar in their general 
preoperative physiological state. However there were some differences between 
the two groups, a significantly higher number of patients in the ERP group had 
evidence of colorectal métastasés on histology compared to the control group. 
There were also a correspondingly higher number of benign cases in the control 
group. Whilst it was attempted to stratify for benign cases in adhering to inclusion 
criteria, all but three patients had suspicions of malignancy. Stratification then 
resulted in one 'benign' patient being randomised to the treatment group and two 
to the control group. As anticipated from the higher number of patients with 
colorectal métastasés in the ERP group, there were also a significantly higher 
number of patients who had received pre-operative neoadjuvant chemotherapy. 
Chemotherapy has two potential effects on the patient: i) it can cause liver 
parenchymal damage putting them at risk of postoperative liver dysfunction 
(Narita 2012); ii) it can reduce a patients cardiovascular fitness, and therefore 
their physiological reserve. A small study showed that neoadjuvant 
chemotherapy reduced both anaerobic threshold and peak exercise capacity by 
10.5% and 11.9% respectively (Hofstetter 2009). With the increased 
physiological demands that major surgery puts on a patient, this could potentially
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have an impact in the postoperative recovery of patients after any major 
operation.
4.2 Operative demographics:
Intraoperative blood loss was similar in both groups. Similar numbers of patients 
had undergone intraoperative clamping of hepatic vessels known as the Pringle 
manoeuvre. However the mean clamping time was slightly longer in the ERP 
group, but this did not reach statistical significance.
There was a higher number of major resections in the ERP group, but this did not 
quite reach statistical significance, and likewise the specimen weights were also 
on average higher in the ERP group 373 versus 180 grams, but again did not 
reach significance. However, not all specimens were weighed by the histology 
department (15 were not weighed), so this may not accurately reflect the true 
size of resection. Similar numbers of patients also underwent preoperative portal 
vein embolization prior to surgery suggesting the number of planned major 
resections were similar in number between groups; or perhaps there were more 
unplanned major resections in the ERP group.
Despite the lack of difference between the two groups in terms of the number of 
major resections and specimen weights, the P-POSSUM operative severity 
score, which includes size of operation, blood loss and histology in its calculation, 
found that scores in the ERP group were significantly higher than the standard 
group, reflecting a more severe surgical insult.
206
4.3 Medical fitness for discharge and hospital length of stay:
In this study the ERP group, despite more patients having had preoperative 
neoadjuvant chemotherapy and higher P-POSSUM operative severity scores, 
still reached discharge criteria significantly sooner compared to the standard 
group (median 3 versus 6 days). The lack of information about timing and criteria 
for discharge within ERP trials has recently been raised (Banz, 2012 page 241) 
in which it was stated that “information on criteria for hospital discharge are often 
missing”. In an attempt to minimise bias an independent, blinded clinician was 
used to assess patients meeting the predefined fitness for discharge criteria. This 
is an important aspect of the study as no previous one in enhanced recovery has 
used a blinded assessor in this way.
The treatment group also had a significant three-day shorter hospital stay and 
makes the result of this study particularly important. Despite the bigger surgical 
insult and more chemotherapy, patients still reached ‘medical fitness for 
discharge’ sooner than standard perioperative care, and as a result a shorter 
hospital length of stay.
There was a five-day reduction in length of stay compared to historical data, and 
is shorter when compared to other published trials looking at an ERP in liver 
surgery. These included a multi-centre pilot laparoscopic study by units 
experienced in enhanced recovery, which demonstrated a median length of stay 
of five days, despite the use of ‘key-hole’ surgery (Stoot 2009). A further brief
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report suggested that hospital stays as short as four days could be possible for 
open surgery and two days for laparoscopic using an ERP (Jensen et al, 2009). 
Age was not a negative criterion for inclusion in our ERP. There were two 
patients in the ERP group over the age of 80 and both went home on POD-3, 
and on average patients over 70 years reached medical fitness for discharge 
sooner in the ERP group when compared to the standard group.
From Hospital Episode Statistics data for 2010-2011 (from the Health and Social 
Care Information Centre) an average of 1600 patients undergo liver resection 
surgery each year, with a median hospital stay of eight days. This study has 
shown that up to 6,400 bed-days per year across the NHS could potentially be 
saved with this programme.
The length of stay in the standard group was also reduced compared to historical 
data. This is likely to be due to a combination of nursing staff learning about ER 
principles and their application to patients in the control group, together with the 
‘Hawthorne effect’, where patients alter their behaviour simply because they are 
being observed in a trial (Roesthlisberger 1939). Patients in this study were not 
blinded and so could potentially be influenced by the fact that they were in a trial 
using enhanced recovery. Another potential bias is that the majority of these 
patients had colorectal métastasés (67% of all patients in the trial), and therefore 
had likely already undergone bowel surgery. With the increasing prevalence of 
enhanced recovery in colorectal surgery many of these patients who have had 
colorectal surgery may have been through an enhanced recovery programme
208
previously. Unfortunately whether or not a patient had been through a previous 
ER programme was not recorded.
The relationship between all the ER elements is complex and it is still unclear 
which of these are the most important. The exact definition of some of the 
elements is also open to interpretation, for example ‘prevention of ileus'. 
Comparison between different ER trials can also be difficult because of the 
different number of ER elements used, but there is also the question of 
compliance with using these elements in different studies. Even in the recent 
LAFA (LAparoscopy and/or FAst track multimodal management versus standard 
care) study (VIug 2011), comparing laparoscopy and open surgery with either ER 
or standard care, compliance was only around 73% (11 of 15 elements) in the 
ER group versus 40% in the control group (6 of 15 elements). A variable 
compliance between elements can lead to even more problems identifying which 
of these improve outcome. Gustafsson and colleagues showed that outcomes 
improved with higher rates of compliance (Gustafsson 2011). In this trial there 
was a high compliance of all elements, due to the fact that two senior research 
fellows followed each patient through their hospital stay. Flowever, it was 
gratifying to note that in the standard group twelve of the nineteen elements were 
already incorporated. These included: pre-operative information, education and 
counselling; pre-operative carbohydrate drinks; perioperative fluid management 
with goal directed fluid therapy; early removal of urinary catheter; perioperative 
nutritional supplements and early mobilisation.
Despite the ERP group incorporating only six extra elements there was still an 
improvement in length of stay and morbidity. Therefore, these elements could be
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the most significant ones. What remains to be determined is whether any or all of 
these elements individually are responsible for the improvement or whether 
benefit comes through combining all the elements to produce a series of 
‘marginal gains', and for an ERP to be fully effective all elements must be 
delivered (Gustafsson 2011).
4.4 Patients in ERP group with prolonged length of stays
Five patients did not successfully follow the ER programme, most commonly as a 
result of surgical complications. One of the first ER patients was a 27 year-old 
woman who had been planned to undergo a central segmentectomy. Flowever, 
due to tumour progression she underwent an unplanned more extensive 
procedure (extended right hemi-hepatectomy) for a high grade pleomorphic 
rhabdomyosarcoma. Due to the original planned smaller resection, this patient 
had not undergone a preoperative PVE and as a result developed hepatic 
insufficiency immediately post-operation. She then developed a bile leak, which 
resolved with conservative management. She met discharge criteria on POD-10 
and was discharged the next day. Unfortunately she was one of two patients who 
required readmission with an abdominal collection, which required draining and a 
biliary stricture which required surgical reconstruction.
The second patient, who stayed for a total of 13 days, underwent a completion 
right hemi-hepatectomy for endometrial secondaries and developed 
postoperatively a persistent bile leak which required an ERCP (Endoscopic 
retrograde cholangiopancreatography). She had met discharge criteria on POD-5
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but because active management of her bile leak was required she had a 
prolonged stay.
The third patient underwent a left hemi-hepatectomy for colorectal secondaries. 
She also developed transient hepatic insufficiency which settled with 
conservative management. This, together with this patient being elderly, she was 
slow to mobilise and despite being independently mobile she also lived alone and 
so stayed for a period of time for rehabilitation, before being discharged on POD- 
17.
The fourth patient underwent two small wedge resections for colorectal 
secondaries and was initially recovering well, until she developed an unfortunate 
unrelated surgical complication of an incarcerated port site hernia from her 
previous laparoscopic colorectal surgery. This required surgical repair and 
delayed her discharge until POD-12.
The final patient underwent a right hemi-hepatectomy for colorectal secondaries. 
He suffered postoperative hepatic insufficiency and developed an abdominal 
collection, both of which were managed conservatively. He had an altered bowel 
habit, and this together with living alone meant that he stayed for a period of 
rehabilitation despite having met discharge criteria.
Because patients were seen each day it was evident that if a patient suffered a 
major complication, in particular hepatic insufficiency, then to follow the ER 
protocol of early mobilisation and feeding was not possible. These patients
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suffered from severe fatigue, and often had a lack of appetite and so had a 
reduced oral intake, which may have exacerbated the problem. As a 
consequence it would always be very difficult for these patients to follow the 
programme and expect to be discharged early from hospital. This is corroborated 
by the data from this study (Table 3.10) which showed that if a patient had a 
complication in the ERP group then their length of stay trebled from a median of 
4 days up to 12 days.
4.5 Morbidity and mortaiity:
The 17.4% overall complication rate in the ERP group compares favourably to 
rates of 37.7% and 41% in two previous studies of ER for open liver resection 
(van Dam 2008, Lin 2011).
A meta-analysis of six RCT's also suggested that ER programmes can 
significantly reduce morbidity (Varadhan 2010). However a large nine-centre 
LAFA (LAparoscopy and/or FAst track multimodal management versus standard 
care) randomised study found no difference in morbidity (Vlug 2011) and agrees 
with the lack of effect on morbidity recorded in this study where although there 
was a reduction from 31% to 14% this did not quite reach a significant level.
Many liver-specific complications (including hepatic insufficiency and bile leak) 
are unlikely to be affected by the introduction of ER elements into liver resection 
surgery, and as such there was no difference in the number of patients with 
these liver complications between the ERP and control groups.
If we exclude liver-related surgical complications and compare non-specific or 
medical complications then a different picture emerges (see Table 3.7). Thirteen
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patients from the standard group had non-liver related complications compared 
to only three patients in the ERP group. The total number of medical 
complications was also significantly reduced from twenty in the standard group to 
only four in the ERP group; and one of these four patients with a ‘medical’ 
complication actually had an unrelated ‘surgical’ problem of an incarcerated port- 
site hernia.
Although there was a reduction in some reduction in individual complications for 
example postoperative chest infections being reduced from five in the standard 
group to one in the ERP group or post-operative ileus reduced from three in the 
standard group to zero in the ERP group, none of these reached statistical 
significance. However, the overall reduction of medical complications may be due 
to early mobilisation and the correct amount of intravenous fluid with 
postoperative goal-directed fluid therapy and therefore less crystalloid volume 
contributing to gut oedema.
Reducing complications may not just have influence over the length of hospital 
stay, but may also have influence on longer-term outcomes. A study by Khun et 
al (2005) showed that a complication within 30 days of major surgery reduced 
long-term survival by up to 69% - from 18.4 to 5.6 years. A similar finding was 
also shown in patients with infective complications after liver resection for 
colorectal métastasés (Farid, 2010). A recent editorial (Fawcett, 2012) has 
suggested that ER may have a role in improved cancer outcomes, due to 
changes in cell-mediated immunity (Snyder, 2010) and by patients being fitter for 
postoperative neoadjuvant chemotherapy more quickly. This could be a very 
important additional benefit for patients undergoing major cancer surgery within 
an ERP, and more work needs to be done in this area.
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One patient died in each of the two groups, both of who had direct complications 
from the surgery itself. Both patients had extensive preoperative neoadjuvant 
chemotherapy and underwent major resections. They subsequently developed 
acute liver failure resulting from having too small a liver remnant or “small-for- 
size syndrome". The first patient, from the ERP group, required a repeat right 
hemi-hepatectomy for colorectal métastasés, a technically difficult procedure and 
associated with 3900 ml blood loss. He quickly developed fulminant liver failure 
and then multi-organ failure and unfortunately passed away on POD-3. The 
second patient, from the standard group also underwent a right hemi- 
hepatectomy for colorectal métastasés. She unfortunately also developed acute 
liver failure but had a much more protracted course in both ICU and ADU and 
passed away on POD-39. As mentioned before these types of complications 
would not be influenced by the introduction of an ERP. An ERP cannot influence 
the amount of liver resected at the time of operation and as a result neither of 
these unfortunate deaths were related, nor could have been prevented, by the 
ERP. The overall mortality rate for all patients was 2.2%, which is similar to both 
the historical rate (Karanjia 2009) from this unit and to rates reported elsewhere 
(Hammond 2011).
4.6 Réadmissions:
One concern of the ERP is that whilst patients are discharged earlier, this benefit 
may be offset by an increase in readmission rates. In one study there was a 
significantly higher rate of réadmissions in the ER group compared with standard 
(Jakobsen et al, 2006). This study was a prospective non-randomised trial which
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compared groups undergoing open colorectal surgery in which 20% in the ER 
group were readmitted compared to only 10% in the standard group.
In this study despite patients being discharged three days earlier than for those in 
the control group there was no statistically significant increase in readmission 
rates. There were only two in the whole study, both of which were in the ERP 
group. This readmission rate is lower compared to other trials in this area, for 
example 13% in and 7.1% in the ER group of two studies (van Dam et al, 2008; 
Lin et al, 2011).
Both these patients had abdominal collections that required draining. The first 
patient required CT guided drainage and stayed for two days. He was originally 
discharged on POD-3 and since he was not re-admitted until POD-20 this was 
unlikely to be directly related to the early discharge. The second patient was less 
straightforward. She was discharged on POD-11, but was quickly readmitted to 
her local hospital with abdominal pain. She was found to have developed an 
abdominal collection and a biliary stricture which required surgical repair, for 
which she stayed for an extra seven days.
4.7 Pain Control:
Both ERP and control groups received epidural analgesia and patients were 
managed in the same way. This can explain why there was no difference in pain 
scores between the two groups on POD-0 (i.e. immediately after the operation). 
From POD-1 to -5 median pain scores were consistently better in the ERP group. 
However none of these reached statistical significance.
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Physical activity and exercise can improve chronic back pain (Hayden 2005) and 
there is evidence that early physiotherapy can improve pain scores and patient 
satisfaction with acute back pain in the Accident and Emergency Department 
(Lau 2008). However, the early and more intense physiotherapy that the 
treatment group received may have contributed to pain scores in the ERP group. 
Of importance, was that early removal of the epidural on POD-2 in the ERP 
group did not make the pain scores worse. This is particularly relevant when we 
compare pain scores on POD-3. Despite patients in the ERP group having had 
epidural anaesthesia stopped and the catheters removed, they had similar pain 
scores to patients in the control group who still have their epidural anaesthesia. 
This meant that ERP patients could mobilise faster and ultimately be discharged 
sooner.
Nearly all patients (93.5%) of the ERP group followed the protocol and had the 
epidural infusions stopped on POD-2. Only three patients did not follow this 
protocol: one epidural fell out accidently on POD-1, which was tolerated well by 
the patient; he was treated with regular oral analgesics with rescue oral morphine 
and he was discharged home on POD-4. With two patients, their epidural 
management was not stopped on POD-2 as both had preoperative chronic pain. 
The first was a 27 year old patient who had been having problems with right 
upper quadrant pain, and was taking preoperative multiple oral analgesics. She 
required a full Mercedes-Benz incision to perform an extended right hemi- 
hepatectomy. The patient developed hepatic insufficiency with altered clotting 
profiles, as a result she was not able to follow the ERP protocol and so a less 
aggressive approach with her epidural management was adopted. Therefore it
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was stopped on POD-3 and the epidural catheter not removed until POD-6 when 
her clotting profile, as assessed by the INR value, had returned to normal. The 
second patient also had chronic pain issues, and had been requiring 90 mg of 
slow release morphine daily. It was considered that her pain would be best 
controlled by continuing epidural management for longer than demanded by the 
ER protocol, and so continued until POD-4.
Epidural catheters were removed on POD-2 as per protocol in 86.9% of cases. 
Six patients did not follow this protocol. The first patient was mentioned earlier 
and his epidural catheter fell out on POD-1. Of the remaining five, three had 
clotting issues and so the catheter could only be removed once the INR had 
returned to normal. The final two were related to pain issues, one was mentioned 
above and was requiring large doses of oral morphine. The second had his 
epidural infusion stopped on POD-2, but this patient had had a large incision and 
the team considered that his pain should be under control prior to removal of the 
catheter on POD-3.
From consideration of the VAS pain scores, early removal of the epidural 
catheter did not negatively affect pain control in the ERP group. In the patient 
satisfaction questionnaire 93.5% of patients in the ERP group were satisfied with 
their pain control, and importantly there were no differences in satisfaction 
between the two groups.
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6.5% of patients in the ERP group had clotting abnormalities, which resulted in a 
delay in removal of their catheter, but with close monitoring of the INR, this could 
be done safely without complications.
4.8 Quality of life:
Our main measure of quality of life was the EQ-5D a validated measure divided 
into two parts: a visual analogue scale and; a descriptive system divided into five 
domains. Both parts were reported by the patient on set postoperative days. The 
EQ-5D Visual Analogue Score for both groups showed an initial drop from the 
preoperative level after the insult of surgery, as one would expect from a record 
of patients’ perception of health state. There was a gradual rise of the scores in 
both groups until POD-28, however they did not quite reach the preoperative 
levels.
The EQ-5D VAS levels were consistently higher in the ERP group throughout the 
perioperative course. In particular, median scores were greater on the third and 
fifth day when patients in the ERP group perhaps felt better about their health 
state because they were either about to go home (POD-3) or managed to be 
discharged home (POD-5). However, these scores did not quite reach 
significance between the ERP and control levels, except on POD-10, the latter 
observation is of interest as patients in both groups would be as both groups 
would have been at home for a number of days at this time.
The VAS score was derived from the patients’ own perception of their health 
state and the lack of preoperative difference is of interest considering the ERP
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group having higher numbers of patients with malignant diagnoses. It is possible 
that patients with a benign diagnosis would be affected differently by the insult of 
surgery from those with a malignancy. Those patients with a malignancy may 
regard surgery as part of their cancer treatment and so will be more positive 
about their health state during the initial recovery after the operation.
However regarding the overall health value index, combined from five domain 
scores, there were significant differences between groups on several 
postoperative days. These scores were significantly greater in the ERP group on 
POD-2, -3, -7, -10 and -14. They were also greater, but did not quite reach 
significant levels, on POD-5 and POD-28. When we compare the 28-day period 
as a whole, by using the area under the curve method, was also a significantly 
improved short-term quality of life over the 28-day period. This quality of life 
difference can be extrapolated to an annualised adjusted measure or Quality- 
Adjusted Life Year (QALY), which makes a number of assumptions, including 
that the quality of life score between groups does not change after the period of 
measurement is over i.e. after POD-28 until day 365. Because previous studies 
have shown no difference after day twenty-one this is a reasonable assumption 
(see section 1.5).
This QALY values were also significantly different between groups. This is an 
important finding when compared to other published trials in this area which 
recorded multi-dimensional scores of quality of life, when none found consistently 
better scores between ERP and control groups.
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When scores are broken down into their different domains an interesting picture 
emerges. The protocol of early mobilisation and intensive physiotherapy, 
together with early removal of the epidural had a big impact on a patient’s 
mobility. On POD-2, -3 and -5 mobility scores were significantly better in the ERP 
group. Almost 30% of patients in the ERP group were independently mobile on 
POD-2 compared with none in the standard group. Even this probably does not 
accurately reflect the full picture; from the physiotherapists’ audit data the ERP 
group had on average 3.9 sessions before being discharged. The 
physiotherapists would only discharge patients once they were deemed to be 
fully independent, so actually our figure of 30% may well be much higher; this is 
because the physiotherapists would have seen them twice a day as per protocol 
and so discharged them at the end of their second session in the afternoon 
whereas we tended to review the patients in the morning. Furthermore, 
improved mobility for patients in the ERP group meant they were able to perform 
self-care sooner. Patients in the ERP group had fewer problems with self-care 
on both POD-2 and -3.
The other important finding in this study was that on POD-28 the ERP group had 
significantly fewer problems in performing their usual activities. This is an 
important finding, as previous studies found no differences found after 21 days 
(section 1.5). The average age of patients in this trial was 65, which is around 
retirement age; however this finding may have benefit to the wider society if 
younger patients could return to work earlier.
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Another observation from examining the health value index domains was that on 
POD-14 the ERP group had statistically less pain or discomfort than the standard 
group. Fifteen patients in the ERP group had no pain compared with only six in 
the standard group. This is also an interesting finding as none of the previous 
studies comparing similar analgesic modalities found any difference in pain 
control beyond six days. The majority of other studies that did find differences in 
pain between ERP and control groups compared different modalities, for 
example epidural with intravenous morphine, so it is perhaps not surprising when 
they found differences between the groups.
From the VAS pain scores of the present study there was no statistical difference 
between groups. The fact that there is no difference between groups is of 
particular importance on POD-3, where there is a marked difference in their 
clinical management. The ERP group have had their epidural and urinary 
catheters removed, and are independently mobile whilst the Control group still 
have their epidural for pain control and only 9% were independently mobile. This 
suggests that early removal of the epidural is not detrimental to a patient’s pain 
management after surgery.
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4.9 Patient satisfaction:
There was no difference in satisfaction rates between groups in any of the 
different questions: “Was there enough pre-admission information?", “Was there 
enough opportunity to ask questions at pre-assessment clinic?", W as pain well- 
controlled?", “Did you start to drink at the correct time?", “Did you start to eat at 
the right time?", “Did you start to walk at the right time?”, “Did you feel that you 
were discharged at the right time?".
Although not statistically significant, there were three patients in the standard 
group compared to only one in the ERR group who felt that they were discharged 
too soon. The patient in the ERR group was the young patient discussed 
previously, who required readmission for drainage of an abdominal collection and 
surgical repair of an ischaemic biliary stricture. Rerhaps not unsurprisingly she 
felt that as she required readmission then perhaps she was discharged too soon.
Two of the three patients in the control group said that they felt their discharge 
was rushed but did not mention specifically why. The final patient in the control 
group felt that his discharge was rushed and that as he lived on his own he 
needed more time to make arrangements. For patients in the ERR group this was 
less of a problem, because from the outset education was very important. This 
included reinforcement of the idea that they will be ready to go home by ROD-3 
or -4, and that arrangements for discharge should be put in place. Therefore with 
this preoperative education about what to expect on a daily basis, including when 
discharge was expected, these issues should be reduced. Retient satisfaction is 
primarily about managing expectation. Ratients with inappropriately high
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expectations may be dissatisfied with optimal care, and in comparison those with 
inappropriately low expectations may be satisfied with sub-optimal care. Overall 
there was no difference in the satisfaction rates between groups. Whilst neither 
group could compare directly with the other, it would have been useful to have 
asked patients in the ERP group who had had a liver resection before to this new 
programme compared with their previous standard perioperative care.
4.10 Community Care
It has to be considered that an early discharge from hospital can transfer the 
burden of care from hospital to community services. The community care 
questionnaire was used at an individual level as part of the economic analysis, 
but was also changed to a categorical simple yes or no as to whether the patient 
used a particular community service. Differences between groups could then be 
tested using a chi-square or Fisher’s exact tests. On review there were no 
significant differences in the use of community services between groups at POD- 
14, apart from significantly fewer patients in the ERP group reporting the need of 
help from friends and relatives at home with normal activities. This was despite 
the patients in the ERP group being at home (following discharge) for an average 
of three days longer. The need for help at home was also lower in the ERP group 
when the questionnaire was repeated on POD- 28, although this did not quite 
reach a statistical level.
Significantly fewer patients in the ERP group visited their GP surgery in the 
second fortnight after discharge. Otherwise there were no differences in 
requests from community services between the groups, other than requiring
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hospital overnight care where four patients in the ERP group needed overnight 
care in hospital, compared to none in the standard group. Two of these patients 
were the re-admissions that have been discussed above and the other two were 
patients with a coincidental diagnosis of HIV, who received some respite care in 
a charitable sexual health clinic because they lived alone, not because they 
required particular hospital treatment.
A study question was evaluation of the impact of early discharge on the use of 
community services. There was in fact a trend towards fewer requirements for 
different services in the ERP group. Only thirteen patients in the ERP group saw 
a GP from discharge to POD-14 compared with twenty-two in the standard 
group. In addition, only twenty-two patients in the ERP group saw a GP practice 
nurse compared to thirty-one in the control group. Furthermore, patients in the 
ERP group also needed significantly less day-to-day help from friends and family. 
This may be due to a combination of early mobilisation and good nutrition to 
enable the patient to manage these activities. This post-discharge improvement 
may also be reinforced in the pre-assessment clinic that although patients will 
feel fatigued it is important to do a certain amount of exercise each day.
4.11 Health Economics
When ERP was compared with standard care there was no difference in either 
anaesthetic or surgical time or costs. This is not surprising as neither surgical nor 
anaesthetic techniques were changed and both were standardised. However 
when the different lengths of stay at different levels of care were compared, 
differences emerged. Whilst there was no difference between groups in the use
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of Level-3 facilities, there was a median cost saving of £826.40 at Level-2 care 
(equivalent to half a day of care at Level-2); and of £502.08 and £151.68 at 
Levels-1 and -0 respectively, roughly the equivalent of a one day saving for each. 
This suggests that on average for the three days of hospital stay that were saved 
by the ERP group, these were evenly spread out over those Levels-2, -1 and -0.
In addition, if a patient in the ERP group had a complication then their average 
stay increased from four days to twelve and their hospital costs correspondingly 
increased by an average of £4106.19 from £6,573.15 to £10,679.34.
When community costs were compared there was no difference between groups. 
Thus, despite being in the community for on average three days longer than the 
standard group, the ERP group did not require more services and overall the 
group total community costs were £2,542 less in the ERP group.
The combined hospital and community costs for an individual were on average 
£837.25 lower in the ERP group. However this was probably an underestimate 
as savings from the pain team were not included; if these were this would add 
another £142.68 of savings yielding a per patient saving of £979.93.
The overall group costs showed a significant £111,367.60 difference between 
groups in favour of the ERP group. However the majority of this difference can be 
explained by two patients in the standard group who experienced extended 
hospital stays, and contributed over £97,500 to the costs of this group. One 
patient stayed for thirty-nine days and his total hospital cost was £34,623.30. The 
second patient unfortunately died from liver failure. She had a prolonged stay in
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level 2 and her hospital costs were £62,921.40. If these two patients are 
removed as outliers then there was still a significant median cost difference of 
£796.81 between the two groups (£7823.88 versus £7027.07, p=0.024).
4.12 Protocol violations
One of the difficult issues with examining ERP trials is when a programme is 
really an ER programme which has nineteen recorded elements for colorectal 
surgery. The question arises if an ERP with ten elements constitutes a genuine 
ERP? The RAPID protocol (Remove, Ambulate, Postoperative Analgesia, 
Introduce Diet) for example used only four of the above 20 interventions and 
reduced LoS from a median of 12 days to 7.5 for open colorectal resections and 
a median of 9.5 to 6 days for laparoscopic procedures (Lloyd 2010).
In this study eighteen of the colorectal ER elements were adopted, only 
‘Laparoscopy and Minimal Incisions' were not adopted as only 5% of liver 
resections are currently performed that way. Although transverse incisions rather 
than midline ones were used, it is unknown if these require less analgesia and 
patients develop fewer pulmonary complications (Brown 2005). However, these 
incisions were often extended cranially in the midline (sometimes called the 
‘Mercedes Benz’ incision), to gain access to the posteriorly located hepatic veins 
and inferior vena cava as part of their dissection. In the control group a number 
of these elements had also been adopted as standard perioperative care and 
these will just constitute good surgical / anaesthetic practice, for example the use 
of VTE prophylaxis or antibiotic prophylaxis.
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The study by shows that the more strictly the protocol is adhered to, the better 
are the outcomes, including 30-day morbidity and réadmissions, Gustafsson et al 
(2011). The LAFA study was criticised due to low compliance of elements in the 
ER groups (Vlug, 2011). In this study there was generally a very high compliance 
with the different elements but in some patients certain elements were omitted. 
For example, 85% of patients in the ERP group had surgical drains however this 
may reflect the increased number of minor resections in the standard group. 
Drains if they were used were removed on average on POD-3 for both groups. A 
recent review on ERAS colorectal principles concludes with respect to peritoneal 
drains: “Routine drainage is discouraged because it is an unsupported 
intervention that probably impairs mobilisation” (Gustafsson, 2012). In our trial 
mobilisation did not seem to been negatively impacted, with 82.2% of the ERP 
group independently mobile by POD-3.
4.13 Limitations of this study
The study was prospective and randomised, but it was not possible to fully blind 
this type of study. The timing and criteria for discharge have recently been 
questioned (Banz, 2012) and so in an attempt to minimise bias an independent, 
blinded clinician was employed to assess patients reaching fitness to medical 
discharge. Previous studies have tried to assess when patients are medically fit 
for discharge but they were not blinded (Varadhan, 2010). In future studies it 
may be advisable to carefully blind the surgeons and use blinded researchers to 
collect the data. The patients themselves however would be impossible to fully
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blind. An essential part of an ERP is that patients are fully engaged in the 
programme and motivated to follow it.
This study was relatively small in terms of patient numbers (but was adequately 
powered for the primary end points), and was a single-centre study. Multi-centre 
trials do have more weight. They encompass a wider population and broader 
range of patients and so can give a better basis for conclusions to be made. 
However they are more difficult to coordinate and are considerably more 
expensive to run.
A recent nine-centre randomised trial (the LAFA study) found no differences in 
morbidity, hospital mortality, quality of life, patient satisfaction, or in-hospital costs 
in fast-track patients undergoing colonic surgery, despite shorter hospital stays 
(Vlug 2011).
Previous studies have been criticised because they only included simple 
resections or compared epidural analgesia with intravenous opiates (Anderson, 
2003; Banz, 2012). In our study we decided to be as inclusive as possible, apart 
from excluding additional procedures we kept it open to all liver resections, 
including re-operations and no upper age limit.
Despite randomisation the ERP and control groups were not identical. There 
were a higher number of major resections in the ERP group, but this gave weight 
to the effectiveness of the programme. Thus, despite having more major 
operations patients in the ERP group reached medical fitness for discharge 
sooner and went home sooner than those in the control group.
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The groups were not stratified for operation size, but often the exact operation 
was not known. A single segment resection could turn into a larger procedure, or 
new métastasés might had developed so a staged procedure would be planned, 
i.e. a wedge or segmentectomy before having a PVE and then a more major 
hepatectomy.
There were also a significantly higher number of patients with malignancy and 
who had undergone preoperative chemotherapy in the ERP group. As discussed 
previously stratification for a benign diagnosis was attempted, but if there was 
doubt over the diagnosis it was assumed that it was malignant for the purposes 
of randomisation. An alternative approach might have been to assume a benign 
diagnosis. However, despite this difference, patients in the ERP group still went 
home sooner.
An additional outcome might have been post-operative fatigue. Post-operative 
fatigue is a known consequence after major surgery, particularly in liver resection 
surgery where patients are also undergoing liver regeneration. We found that 
patients in the ERP group needed significantly less help at home with normal 
activities from friends and family and this may be due to less fatigue in these 
patients. In retrospect it would have been interesting to evaluate the impact of 
postoperative fatigue in the two groups of patients.
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4.14 Future directions
The ER protocol was based on those elements developed for colorectal surgery, 
some of these may not be ideal for liver surgery and there may be more liver- 
specific elements that could be incorporated.
Future studies could concentrate on individual elements or more adaption of 
specific elements for liver surgery. Whilst this study showed that the programme 
as an entity is successful, future studies should evaluate how individual elements 
can affect outcomes.
Epidural analgesia has always been considered the gold standard for open 
abdominal surgery, however the incisions required for this procedure are right­
sided and transverse. Thus, consideration for future studies could be made 
using different analgesic modalities including paravertebral block. Although that 
would not cover incisions that cross the midline so perhaps an infusion of local 
anaesthetic via a wound catheter may be more effective in these cases.
Despite the earlier mobilisation in the ERP group in this study, others have 
demonstrated earlier returns to full mobilisation. Koea and colleagues (2009) 
used intrathecal morphine in their fast-track programme and despite higher pain 
scores compared to the historical group (where epidural analgesia was used) 
they demonstrated 100% of patients were independently mobile on the first 
postoperative day. A recent study performed at the Royal Surrey County 
Hospital we found that in the twelve months after this trial ended our length of 
stay has increased to 5 days (Mathers 2014), the main reason for this was the 
epidurals being removed at a later stage than trial protocol, and so delaying
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discharge. A potential new study could be to combine the mobilisation benefits of 
intrathecal opiates with a wound catheter and compare it to the gold standard 
epidural analgesia and see if independent mobilisation could be achieved and 
therefore earlier discharge.
What is the impact of goal-directed fluid therapy on liver function, when 
compared with standard fluid therapy and does the type of fluid impact on liver 
function? In this study the overall amount of intravenous fluid was the same in 
both groups at six and twenty-four hours. Although the ratio of colloid / crystalloid 
was different, in that patients in the ERP group had significantly more colloid in 
both the first six and twenty-fours hours after surgery.
A recent ICU study (Perner 2012) compared colloid versus crystalloid fluid 
resuscitation and showed that for patients treated with colloids (Hydroxyethyl 
starch ) there was an increased risk of death (relative risk 1.17; 95% confidence 
interval [Cl] 1.01 to 1.36; p=0.03); and an increased need for renal replacement 
therapy (relative risk 1.35; 95% 011.01 to 1.80; p=0.04). However this population 
was different from that were in this study; they were patients admitted to ICU with 
severe sepsis. It is unknown what impact this has on the type of fluid therapy 
needed for an elective surgical population.
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4.15 Conclusions
This study has shown that an ERP is safe and reductions in LoS are easily 
achieved in open liver resections. Post-operative stays of only three days are 
also possible (33% of the ERP group were discharged home on POD-3). An 
ERP also significantly reduced medical complications, which may have longer- 
term benefits.
The ERP for open liver resection was also associated with an improved quality of 
life and QALY. In particular the ERP group were able to return to usual activities 
significantly sooner than the control group. Costs were also reduced by an 
average of £837.25 over a 28-day postoperative period.
However these short stays are only possible if the patient avoids complications. 
The presence of a complication in this trial increased the median length of stay 
threefold (and the median cost almost doubled; so it is necessary to continue to 
find strategies to reduce perioperative morbidity. This is particularly important for 
patients undergoing cancer surgery as a complication could influence long-term 
survival (Ito, 2008; Farid, 2010).
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Appendix 1
Patient Information Sheet 
Clinical Trial for Patients having Liver Resection
You are being invited to take part in research running at the Royal Surrey County 
Hospital in collaboration with the University of Surrey. Before you decide if you 
would like to be involved, it is important for you to understand why the research is 
being done and what it will involve. This information sheet will help you 
participate in this research. Please take time to read the following information 
carefully. You may find it helpful to discuss this information sheet with your 
family/loved ones, if you so wish.
What is a clinical trial?
A clinical trial is a scientific method of collecting information on the effectiveness 
and safety of new treatments. Although new treatments are always developed 
with the intention of improving patient care, it is necessary to conduct clinical 
trials comparing these new treatments with the current ones in order to show 
whether they are indeed better.
What is the purpose of this clinical trial?
The purpose of this clinical trial is to evaluate a new pathway of care for patients 
having liver resection surgery, to see whether or not it can produce improved 
clinical outcomes, reduced complications, a quicker recovery from surgery and a 
better patient experience. The new pathway comprises a number of changes to 
the way in which we look after our patients (both before and during their hospital 
stay).
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These changes include more information about expected progress and 
discharge; early mobilisation and return to normal living after surgery. We hope 
that these changes will improve the high standard of care our unit provides by 
encouraging a speedy recovery from surgery and improve patient satisfaction. 
This new pathway has been used very successfully in other surgical specialties 
but has not been used for patients undergoing liver resections. In order to prove 
that it is effective and worthwhile we need to conduct a trial.
Who is conducting the trial?
This trial is being conducted by a clinical research team comprising a number of 
specialist doctors and nurses:
Dr Nial Quiney- Principal Investigator (Consultant Anaesthetist)
Dr Matt Dickinson -  Consultant Anaesthetist 
Dr Mike Scott -  Consultant Anaesthetist 
Dr Chris Jones -  Anaesthetic Clinical Research Fellow 
Dr Leigh Kelliher -  Anaesthetic Clinical Research Fellow 
Laura Spring -  Clinical Nurse Specialist for Liver Surgery
We are all based at the The Royal Surrey County Hospital NHS Foundation 
Trust, who is also sponsoring the trial.
We are also working closely with colleagues at the University of Surrey. Dr 
Tushna Vandrevala, is a health psychologist. Dr Heather Gage is a health 
economist and Dr Sig Johnson is a statistician. They will be analyzing the data.
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No personal information from your medical records or other sources will be given 
to the researchers at the University of Surrey.
Why have I been chosen?
All adult patients due to have an elective open liver resection are being invited to 
participate.
What does taking part in the trial require from me?
You will be approached by a member of the research team at your routine pre­
assessment appointment. You will have a chance to discuss the trial in more 
depth and ask any questions they might have regarding it. If you agree to 
participate, you will then be randomly assigned to one of two groups. One group 
will follow the pathway of care that we currently give to all our patients. The other 
group will follow the new pathway, comprising all the elements of the current 
pathway as well as some additional components.
You will be asked to fill out a short questionnaire prior to the operation. This 
questionnaire is designed to assess your general health and well being. It will be 
given to you by a member of the research team, who will explain how to fill it out. 
It should take no more than 5 minutes. You will also be asked to fill out the same 
questionnaire on 7 occasions after the operation (days 2, 3,5,7,10,14 and 28).
As part of your stay in hospital after the operation, routine blood samples are 
collected to monitor your recovery. During this time we will collect some 
additional blood samples from you and will not require any extra 
injections/needles above those you would normally need. The blood samples will 
be analyzed in laboratories at the Royal Surrey County Hospital.
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If you are allocated in the group that follows the new pathway, we will be invited 
to participate in a short interview. The first interview will take place before your 
operation, and you will be asked to talk about what your thoughts about your 
operation and what information you have received from the doctors. This 
interview can take place in the Hospital, and will last 15-20 min.
The second interview will take place 2 or 3 days after you return home from the 
operation.
You will be asked about experiences in the hospital, discharge and recovery at 
home.
Depending on your preference, this interview will take place in your home or on 
the telephone. This interview will last 20-30 min.
If you agree, the interview will be audio-taped as this improves the ability to recall 
the information provided at interview and helps the researcher to provide an 
accurate account of your experiences. All taped interviews will be stored in a 
locked cupboard and transcripts of interviews will be made anonymous.
Do I have to take part?
It is up to you if you decide to join the study. After you have read this leaflet and 
we have decided that you are suitable to be included in the trial, you will have a 
further opportunity to discuss the trial with one of our specialist’s nurses or 
research fellows.
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We will ask you to return to the hospital before the operation for an assessment 
of your general health (pre-assessment). If you are happy to be included in the 
trial we will need to get your written consent.
You are free to withdraw from the study at any time without giving a reason. This 
will not affect the standard of care you receive.
What are the benefits of the procedure?
Both groups will receive a very high standard of care. Patients often join trials to 
help improve medical knowledge or in the hope of gaining benefit from a new 
treatment that could improve care for patients suffering from similar conditions. 
The main objective of this study is to see if the new pathway can improve the 
experience patients have of surgery, improve their recovery and reduce 
complications. We hope that this new pathway will improve the high quality care 
our unit provides to patients undergoing liver surgery.
What happens when the study stops?
Your follow up after your procedure will be unaffected. You will be seen by your 
doctors as you would were you not in the study.
Will my taking part be kept confidential?
All the information about your participation in this study will be kept confidential. 
No one other than the clinical research team will have access to your medical 
records.
All data collected will be anonymised and stored in a secure file within the Royal 
Surrey County Hospital research and development department. The data will be
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analysed by researchers at the University of Surrey but they will not have access 
to any personal data or medical records. They will be only given a file with the 
data which does not contain any personal details. The blood samples will be 
analysed at the University of Surrey. At the end of the trial samples will be 
destroyed according to the trusts’ regulatory procedure.
If you are interviewed, all audio recordings will be kept in a locked cupboard and 
will be erased when the study has been completed. Any information that may 
identify you will be made anonymous -  for example, where you live will not be 
identified, and neither will your name or any names of specific doctors involved in 
your care.
What will happen to the results of the study?
The information from this trial may lead to publications within peer-reviewed 
journals, but this will be anonymous. Your personal information will never be 
used.
Who has reviewed the study?
The study has been reviewed by the Surrey Research Ethics Committee, which 
has raised no objections.
If you have any further questions, please contact
Dr Chris Jones Anaesthetic Research Fellow: 07899894389
Dr Leigh Kelliher Anaesthetic Research Fellow: 07813659948
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If you have any complaints about the trial please contact: 
Dr Nial Quiney Consultant Anaesthetist: 01483 464116 
Department of Anaesthetics 
Royal Surrey County Hospital
REC REFERENCE NUMBER 10/H1109/83 V.03 (16.03.11)
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Appendix 2
Royal Surrey County Hospital
NHS Foundation Trust
Consent Form
Title of Project: Enhanced Recovery in Liver Resection
Name of Researchers: Dr Chris Jones & Dr Leigh Kelliher
Please initial box
I the undersigned voluntarily agree to take part in the study on
I confirm that I have read & understood the information sheet given to me. I have had the 
opportunity to consider the information, ask questions and have had these answered satisfactorily
I agree to comply with any instruction given to me during the study and to co-operate fully with 
the investigators. I shall inform them immediately if  I suffer any deterioration of any kind in m> 
health or well-being, or experience any unexpected or unusual symptoms.
I understand that all personal data relating to volunteers is held and processed in the strictes 
confidence, and in accordance with the Data Protection Act (1998). I agree that I will not seek tc 
restrict the use of the results of the study on the understanding that my anonymity is preserved.
I understand that my participation is voluntary and that I am free to withdraw at any time, without  ^
giving any reason, without my medical care or legal rights being affected.
I understand that relevant sections of my medical notes and data collected during the study may 
be looked at by the clinical research team from the Royal Surrey County Hospital. I give 
permission for the researchers to access my records.
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I agree that blood samples will be obtained. I understand these are additional to normal practice 
that they will not affect or delay my treatment. I agree that blood samples will be transferred to 
the University of Surrey for analysis.
I confirm that I have read and understood the above and freely consent to participating in this 
study. I have been given adequate time to consider my participation and agree to comply with th( 
instructions and restrictions of the study.
Name of volunteer (BLOCK CAPITALS)
Signed
Date
In the presence of (name of witness in BLOCK CAPITALS)
Signed
Date
Name of researcher/person taking consent (BLOCK CAPITALS)
Signed
Date
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Appendix 3
Royal Surrey County Hospital
NHS Foundation Trust
Clinical Trial for Patients Having Liver Resection
Surgery
Data Coilection 
Booklet
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Pre-op
C o n sen t: □
Fortisips:
G iven  to pt: (9  in to ta l) □
T a k e n : □
C a rb o h y d ra te  drink (p re -o p ):
G iven  to pt: □
T a k e n : (x 8 )2 1 :0 0  night b e fo re  □
(x 4 )2  hours p re -o p  □
Blood tes t (1 ) on c a n n u la  insertion □
E Q 5 D : □
Demographic details:
H eight:
W eig h t:
P M H x :
D rug Hx:
A S A : . . . . . . . . . .
A g e : . . . . . . . . . . . .
S e x : . . . . . . . . . . . .
P V E ?  Y d  N □
P re -o p  chem o: Y d  N d
C P E X  Y d  N d
I fY :  A T
V 0 2  m a x
D a te  fin ished:
P-POSSUM:
Physiological Variables:
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A g e:
C a r d ia c :  No cardiac failure □
Diuretic, digoxin, Tx for angina or BP □
Peripheral oedema, warfarin, borderline cardiomyopathy □
Raised JVP, cardiomyopathy □
R e s p i  No dyspnoea □
Dyspnoea on exertion, mild COPD □
Limiting dyspnoea, mod COPD
Dyspnoea at rest, puimonary fibrosis/consolidation on CXR □
E C G : EGG Normal □
EGG = AF rate 60-90 □
EGG= any other abN rhythm, >4/min ectopics, Q waves, ST/T changes □
S ysto lic  BP:
P u ls e  rate:
Hb: (g /d L )
W B C :
U rea:
S odium :
P otassium :
G C S :
Operative Parameters:
O p e ra tio n  typ e  = m a jo r +
N o  o f p ro ced u res  = o n e
O p e ra tiv e  blood loss: <ioomis □
101-500 mis □
501-999 mis □
>1000 mis □
P erito n ea l co n tam in atio n  : no soiling
M a lig n a n c y  status: not malignant □
Primary malignancy only 
Malignancy + nodal mets
Malignancy + distant mets □
G E P O D : Elective
Physiology score: .....................
Operative severity score: .....................
Morbidity %  (from  P O S S U M ) . . . . . . . . . . . . . . . . .
Mortality % ....................
REVISED CARDIAC RISK INDEX
(Lee Circulation 1999; 100:1043-1049)
Each risk factor is assigned one point.
273
1. High-risk surgical procedures □
• Yes
2. History of ischemic heart disease □
• History of myocardial infarction
• History of positive exercise test
• Current complain of chest pain considered secondary to myocardial ischemia
• Use of nitrate therapy
• ECG with pathological Q waves
3. History of congestive heart failure □
• History of congestive heart failure
• Pulmonary edema
• Paroxysmal nocturnal dyspnea
• Bilateral rales or S3 gallop
• Chest radiograph showing pulmonary vascular redistribution
4. History of cerebrovascuiar disease □
• History of transient ischemic attack or stroke
5. Preoperative treatment with insulin □
6. Preoperative serum creatinine >150 pmoi/L □
RISK OF MAJOR CARDIAC EVENT
Points Class Risk
0 I 0.4% □
1 II 0.9% □
2 III 6.6% □
3 or more IV 11 % □
"Major cardiac event" includes myocardial infarction, pulmonary edema, 
ventricular fibrillation, primary cardiac arrest, and complete heart block
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Post-op (ICU)
T im e  Z e ro  (ie  en d  o f liver resection): . . . . . . .
T im e  o f End o f S urgery: .....
P o s t-o p  b l0 0 d s (2 )- 6 hours post-liver resection □
O ra l fluids: □
O ra l diet: □
T im e  from  en d  o f su rg ery  to first oral in ta k e :.....
B ow el sounds: Y d  N d
Flatus: Y d  N d
B ow els  open: Y d  N d
M obilising: d
T im e  from  en d  o f su rg ery  to m o b ilisa tio n :. . . . . . . . . .
P a in  score: 
V A S  0 -1 0
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Surgical data:
O p era tio n  perfo rm ed:
W e ig h t o f liver resected : 
C om plications:
B lood loss:
P rin g le  m an o eu vre : Y d  N d
L ength  o f c lam ping: m ins  
D uration  o f operation :
T im e  o f induction:
K nife  to skin:
End o f operation:
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Continuation chart in ICU
Hours 1 2 3 4 5 6 24
Pulse
MAP
UO
Fluid vol: 
Colloid
Crystalloid
O ther(FFP  
etc)
Vasopressors
Inotrope
Cv02
Lactate
aC 02
m vC02
Intubated?
For standard group: which end point used: ?Lactate, CVP, Cv02 etc 
Insulin: Y d N □
Total fluid given:
6 hours;
24 hours: 
Blood given: 
Clotting Factors:
Y d N D No. of Units:
FFP:
Pits:
Cryo:
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Post-op Day 1 ICU
B loods (3): 24hrs post KTS 
T o le ra tin g  O ra l intake: 
B ow el sounds:
Flatus:
B ow els  open:
M obilising:
T o  chair:
T o  w ard: 
In d ep en d en t:
P ain  score:
□
□
□
R e s c u e  a n a lg e s ia  u sed ?  
D o s e  o f m o rp h in e  n eed ed :
Y d  
Y  D 
Y d  
Y d  
Y d
D
N d  
N D 
N D 
N D 
N d
S urg ica l d ra ins  out: Y  D N D
C en tra l line out: Y d N D
IV I s topped: Y d N D
U rin ary  C a th e te r  out: Y d N D
E pidural out: Y d N D
NB: W rite  up reg u la r a n a lg e s ia  fo r E R P  group  (P R N  fo r s ta n d a rd )  
P a ra c e ta m o l 1 g B D  (if l f t s  o k )
T ra m a d o l 5 0 m g  T D S
V o ltaro l 5 0 m g  B D /T D S  (if serum creat <110 mmol/L)
Plus rescu e  O ra m o rp h  10m g 3 hourly.
Post-op day 2 ICU
D iam o rp h in e  3m g  v ia  ep idura l am
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B loods (4): 48 hrs post liver resection D
T o le ra tin g  O ra l in take: Y d N d
B ow el sounds: Y d N D
Flatus: Y d N D
B o w els  open: Y d N D
M obilising: Y d N d
T o  chair: □
T o w a rd :  □
In d ep en d en t: □
P a in  s c o re :. . . . . . . . . . . . . . . . . .
R e s c u e  m o rp h in e  used  (T o ta l m g):
S u rg ica l d ra ins  out: Y d N D
C e n tra l line out: Y d N D
IV I stopped: Y d N D
U rin ary  C a th e te r  out: Y d N D
E pidura l out: Y d N D
E Q 5 D : □
T im e  out
(hours post-op)
T im e  out 
T im e  off 
T im e  out 
T im e  out:
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Post-op day 3
L evel?  1,2,3 etc
B loods (5): 72 hrs post D
T o le ra tin g  O ra l intake: Y n N d
B ow el sounds: Y d N D
Flatus: Y d N D
B ow els  open: Y d N D
M obilising:
T o  chair: □ 
T o  w ard : □ 
In d ep en d en t: □
Y d N d
P ain  s c o re :. . . . . . . . . . . . . . . . . .
T o ta l m orph ine  re s c u e  in last 2 4  hours:
S u rg ica l d ra ins  out: Y d N D T im e  out
(hours post-op)
C e n tra l line out: Y d N D T im e  out
IV I s topped: Y d N D T im e  off
U rin ary  C a th e te r  out: Y  □ 
(+  n eed  fo r re -ca th e te ris a tio n  Y /N )  
E pidura l out: Y  □
N D 
N D
T im e  out 
T im e  out:
E Q 5 D : □
P O M S :
Pulmonary: □ Infectious: D Renal: □
Gl:
Haem:
□
□
CVS:
Wound:
□
□
Neuro:
Pain:
□
□
Defn see below:
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Pulmonary: P t d e v e lo p e d  a n e w  re q u ire m e n t fo r 0 2  o r resp  support
Infectious: C u rren tly  on antib io tics  + /o r  T e m p  > 3 8  °C  in last 2 4  hr
Renal: O lig u ria  (< 5 0 0  ml in 2 4  hr), f  se ru m  c re a t (> 3 0 %  o f p re -o p
leve l), re -c a th e te ris e d .
Gl: U n a b le  to to le ra te  an  en te ra l d ie t fo r a n y  reaso n  inc N + V ,
ab d o  d istension
CVS: N e w  M l, isch aem ia , |B P  requiring fluid o r inotropes, atrial
or ven tricu la r arrh yth m ia , card io g en ic  p u lm o n ary  o e d e m a , th rom botic  
even t.
Neuro: N e w  foca l o r neuro log ica l deficit, confusion , delirium  or
co m a
Haem: N e e d  fo r blood, pits, F F P  or cryo
Wound: w o u n d  d e h is c e n c e  requiring  surg ical exp lo ra tio n  or
d ra in a g e  o f pus
Pain: n e w  post-op  pain requiring p a re n te ra l op io ids
Post-op dav 4:
L eve l?  1,2,3 etc ...............
T o le ra tin g  O ra l intake:
B ow el sounds:
Flatus:
B ow els  open:
M obilising:
T o  chair:
T o  w ard:
In d ep en d en t:
P ain  s c o re :. . . . . . . . . . . . . . .
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Y d N d
Y d N D
Y d N D
Y d N D
Y d N d
□
□
□
T o ta l m o rp h in e  rescu e  in last 2 4  hours:
S u rg ica l d ra ins  out: Y d  N d  T im e  out
(hours post-op)
C en tra l line out: Y d  N d  T im e  out
IV I s topped: Y d  N  d  T im e  off
U rin ary  C a th e te r  out: Y d  N d  T im e  out
(+  n eed  fo r re -ca th e te ris a tio n  Y /N )
E p idura l out: Y d  N d  T im e  out:
Post-op dav 5:
Level?  1,2,3 etc........................................
T o le ra tin g  O ra l in take: Y d  N d
B ow el sounds: Y d  N d
Flatus: Y d  N d
B ow els  open: Y d  N d
M obilising: Y d  N d
T o  chair: d
T o w a rd :  d
In d ep en d en t: d
P ain  s c o re :. . . . . . . . . . . . . . . . . .
T o ta l m o rp h in e  rescu e  in last 2 4  hours:
S urg ica l d ra ins  out: Y  d  N d  T im e  out
(hours post-op)
C en tra l line out: Y d  N d  T im e  out
IV I s topped: Y d  N d  T im e  off
U rin ary  C a th e te r  out: Y d  N d  T im e  out
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(+  n eed  fo r re -ca th e te ris a tio n  Y /N )
E p idura l out: Y d  N d  T im e  out:
EQ5D: D
POMS:
Pulmonary: d  Infectious: d  Renal: d
Gl: D CVS: d  Neuro: d
Haem: d  Wound: d  Pain: d
D is c h a rg e  criteria  m et?: d
If not w h y  n o t:....
-G o o d  pain control w ith oral a n a lg e s ia  d
-T o le ra n c e  o f solid food d
- In d e p e n d e n tly  m obile  d
-N o rm a l o r d ecreas in g  s eru m  bilirubin d
-P a tie n t w illing to be d isch arg ed  d
Post-op dav 6
Level?  1,2,3 etc ...............
P ain  s c o re . . . . . . . . . . . . .
T o ta l m orph ine  rescu e  in last 2 4  hours:
D isch arg e  criteria  m et?: d
If not w h y  n o t:....
-G o o d  pain control w ith oral a n a lg e s ia  d
-T o le ra n c e  o f solid food d
-In d e p e n d e n tly  m obile  d
-N o rm a l or d e creas in g  seru m  bilirubin d
-P a tie n t w illing to  be d isch arg ed  d
Post-op dav 7
Level?  1,2,3 etc ...............
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P ain  s c o re . . . . . . . . . . . . .
T o ta l m o rp h in e  re s c u e  in last 2 4  hours:
EQ5D:
D isch arg e  criteria  m et?: □
If not w h y  n o t:....
-G o o d  pain control w ith  oral a n a lg e s ia  □
-T o le ra n c e  o f solid food □
-In d e p e n d e n tly  m obile  □
-N o rm a l o r d ec re a s in g  seru m  bilirubin □ 
-P a tie n t w illing to  be  d isch arg ed  □
Post-op dav 8
P ain  s c o re . . . . . . . . . . . . .
T o ta l m o rp h in e  rescu e  in last 2 4  hours:
POMS:
Pulmonary: □ Infectious: □ Renal: □
Gl: □ CVS: □ Neuro: □
Haem: □ Wound: □ Pain: □
D isch arg e  criteria  m et?: □
If not w h y  n o t:....
-G o o d  pain control w ith oral a n a lg e s ia  □
-T o le ra n c e  o f solid food □
-In d e p e n d e n tly  m ob ile  □
-N o rm a l o r d ec re a s in g  seru m  bilirubin □ 
-P a tie n t w illing to be d isch arg ed  □
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Post-op dav 9
P ain  s c o re . . . . . . . . . . . . .
T o ta l m o rp h in e  re s c u e  in last 2 4  hours:
D is c h a rg e  criteria  m et?: □
If not w h y  n o t:....
-G o o d  pain control w ith oral a n a lg e s ia  □
-T o le ra n c e  o f solid food □
-In d e p e n d e n tly  m obile  □
-N o rm a l o r d e creas in g  seru m  bilirubin □
-P a tie n t w illing to be d isch arg ed  □
Post-op dav 10
E Q 5 D : □
P a in  s c o re   . . . .
T o ta l m o rp h in e  rescu e  in last 2 4  hours:
D is c h a rg e  criteria  m et?: □
If not w h y  n o t:....
-G o o d  pain control w ith oral a n a lg e s ia  □
-T o le ra n c e  o f solid food □
-In d e p e n d e n tly  m obile  □
-N o rm a l or d e creas in g  seru m  bilirubin □
-P a tie n t w illing to be d isch arg ed  □
Post-op dav 11
P ain  s c o re . . . . . . . . . . . . .
T o ta l m o rp h in e  rescu e  in last 2 4  hours:
D is c h a rg e  criteria  m et?: □
If not w h y  n o t:....
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-G o o d  pain control w ith  oral a n a lg e s ia  □
-T o le ra n c e  o f solid food □
-In d e p e n d e n tly  m ob ile  □
-N o rm a l o r d ec re a s in g  seru m  bilirubin □ 
-P a tie n t w illing to be  d isch arg ed  □
Post-op dav 12
P ain  s c o re . . . . . . . . . . . . .
T o ta l m o rp h in e  rescu e  in last 2 4  hours:
D isch arg e  criteria  m et?: □
If not w h y  n o t:....
-G o o d  pain control w ith oral a n a lg e s ia  □
-T o le ra n c e  o f solid food □
-In d e p e n d e n tly  m obile  □
-N o rm a l o r d e creas in g  seru m  bilirubin □ 
-P a tie n t w illing to be d isch arg ed  □
Post-op dav 13
P ain  s c o re . . . . . . . . . . . . .
T o ta l m o rp h in e  rescu e  in last 2 4  hours:
D isch arg e  criteria  m et?: □
If not w h y  n o t:....
-G o o d  pain control w ith oral a n a lg e s ia  □
-T o le ra n c e  o f solid food □
-In d e p e n d e n tly  m obile  □
-N o rm a l o r d ecreas in g  seru m  bilirubin □ 
-P a tie n t w illing to be d isch arg ed  □
Post-op dav 14
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E Q 5 D : □
P ain  s c o re . . . . . . . . . . . . .
T o ta l m o rp h in e  rescu e  in last 2 4  hours:
D isch arg e  criteria  m et?: □
If not w h y  n o t:....
-G o o d  pain control w ith  oral a n a lg e s ia  □
-T o le ra n c e  o f solid food □
-In d e p e n d e n tly  m ob ile  □
-N o rm a l or d e creas in g  seru m  bilirubin □
-P a tie n t w illing to be  d isch arg ed  □
Post-op dav 15
P O M S :
Pulmonary: □ Infectious: □ Renal: □
Gl: □ CVS: □ Neuro: □
Haem: □ Wound: □ Pain: □
P ain  s c o re . . . . . . . . . . . . .
T o ta l m o rp h in e  rescu e  in last 2 4  hours:
D isch arg e  criteria  m et?: □
If not w h y  n o t:....
-G o o d  pain control w ith oral a n a lg e s ia  □
-T o le ra n c e  o f solid food □
-In d e p e n d e n tly  m obile  □
-N o rm a l or d e creas in g  seru m  bilirubin □ 
-P a tie n t w illing to  be d isch arg ed  □
Post-op dav 28
E Q 5 D : □
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Summary Sheet
D a te  o f o p era tio n  :  / . . . . . . . / . . . . . .
O p era tio n  perfo rm ed:
D a te  d isch arg e  criteria  m et: . . . . . . / . . . . . . . / . . . . . .
A ctua l d isch arg e  date : . . . . . . / . . . . . . / . . . . . .
P L o S :  d ays
T im e  to first oral in take  post-op  . . . . . . . . . . . . . . hrs
T im e  to m obilisation  post-op  . . . . . . . . . . . . . . hrs
D ays  in level 3 : . . . . . .
D ays  in level 2 : .....
D ays  in level 1 : .....
D ays  in level 0: . . . . . . .
E Q 5 D :
P re -o p  □
D a y  2 □
D a y  3 □
D a y  5 □
D a y  7 □
D a y  10 □
D a y  14 □
D a y  28 □
P O M S  3 d  5 d  8 D 15 D
P atien t S atis factio n  Q u e s tio n n a ire  d
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Blood continuation sheet:
P re -o p 6  hrs 2 4  hrs 4 8  hrs 7 2  hrs
P T
A P T T
IN R
H b
W C C
Pits
A L T
A L P
Bill
Insulin
C ortisol
C R P
G lu co se
IL -2
IL -4
IL -6
IL -8
IL -1 0
G M -C S F
In terferon
Y
T N F -a
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C D -3
C D -4
C D -8
C D 4 5
R O
H L A -D R
C D -5 6
C D -1 6
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Appendix 4
Liver Surgery Enhanced Recovery Programme
A  P a t ie n t  C h e c k lis t &  In fo rm a t io n  B o o k le t
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Introduction
The enhanced recovery programme for liver surgery is about improving the outcome of 
your surgery, speeding up your recovery period and reducing complications after your 
surgery. For the programme to be successful it is important that you participate in your 
own recovery programme, taking responsibility for certain aspects of your recovery and 
care. These include:
Optimizing your pre-operative health status
Reducing postoperative complications by changing the traditional surgical and 
anaesthetic methods
Early feeding after your operation
Early mobility after your operation
Setting nutritional & activity goals that need to be achieved before your discharge 
home
Your daily goals will begin a few days before your surgery and your cooperation is 
important for the operation and your recovery to go well.
The following sections outline what you are expected to achieve before and after your 
operation. Please take time to read the whole document and start to fill in the sections 
prior to coming to hospital. You will notice that there are only five days for you to fill in 
after your operation. This is because we are aiming for you to be ready to go home at 
this time.
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Three days before your operation
(please tick the relevant boxes once completed)
Date
Drink one bottle of Fortisip three times a day
10am □ 2pm □ 6pm □
Two days before your operation
(please tick the relevant boxes once completed)
Date
Drink one bottle of Fortisip three times a day
10am □ 2pm □ 6pm □
One day before your operation
(please tick the relevant boxes once completed)
Date
Drink one bottle of Fortisip three times a day
10am □ 2pm □ 6pm □
Take the ‘Pre-Op’ drink as instructed 9pm □ 
(4 cartons = 800 mis total)
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Morning of Surgery
(please tick the relevant boxes once completed)
Take the ‘Pre-Op’ drink as instructed 5.30am □
(2 cartons = 400mls total)
After Surgery
(please tick the relevant boxes once completed)
Drink one bottle of Fortisip two times after your surgery, if possible
1.D 2. □
Eat an evening meal, if possible
% Portion □ % Portion □ Full Portion □
If you did not eat, why?
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Post-op Day One (please tick the relevant boxes once completed)
Drink one bottle of Fortisip three times a day
10am □ 2pm □ 6pm □
Diet
% Portion %
Portion
Full
Portion
If you did not eat, why?
Breakfast
Lunch
Dinner
It is important to start to mobilize, e.g. standing, sitting out in a chair or marching on the 
spot, rather than lying in bed. Therefore you should expect to mobilize with the 
physiotherapist (once a day) and the nursing staff (twice a day)
Physiotherapist Yes □ No o Why not?
Nurses
Morning Yes □ No □ Why not?
Afternoon Yes □ No O Why not?
If there have been no complications you can expect to have any surgical drains removed 
by the end of the day
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Surgical drains out? Yes □ No □ N/A □ Why not?
By the end of the day you should be able to take oral painkillers
Commenced oral painkillers? Yes □  No □  Why not?
You should start to think about what things need to be achieved before you can be 
discharged home
Adequate pain control requiring only oral painkillers Yes □ No □
Adequate oral intake (food & drink) Yes □ No □
Bowels opened Yes □ No □
Passing urine Yes □ No □
Independent mobility Yes □ No □
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Post-op Day Two (please tick the relevant boxes once completed)
Drink one bottle of Fortisip three times a day
10am □  2pm □  6pm □
Diet
% Portion Yz
Portion
Full
Portion
If you did not eat, why?
Breakfast
Lunch
Dinner
Your epidural, central line (in your neck), drips in your arms and urinary catheter should 
be removed or disconnected this morning to help you mobilize
Epidural out? Yes □ No □ Why not?
Drips out or disconnected? Yes □ No □ Why not?
Catheter out? Yes □ No □ Why not?
It is important to start to mobilize rather than lying in bed, therefore you are expected to 
mobilize with the physiotherapist (once a day) and the nursing staff (twice a day). Today 
you should also aim to take a short walk on the ward
Physiotherapist Yes □  No □  Why not?
Nurses
Morning Yes □ No O Why not?
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Afternoon Yes □ No □ Why not?
Pain relief. Commenced oral painkillers?
Yes □  No O Why not?
If there have been no complications you can expect to have any surgical drains removed
Surgical drains out? Yes □  No □  N/A □  Why not?
You should start to think about what things need to be achieved before you can be 
discharged home
Adequate pain control requiring only oral painkillers Yes □ No □
Adequate oral intake (food & drink) Yes □ No □
Bowels opened Yes □ No □
Passing urine Yes □ No □
Independent mobility Yes □ No □
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Post-op Day Three (please tick the relevant boxes once completed)
Drink one bottle of Fortisip three times a day
10am □  2pm □  6pm □
Diet
% Portion Yz
Portion
Full
Portion
If you did not eat, why?
Breakfast
Lunch
Dinner
Your epidural, central line (in your neck), drips in your arms and urinary catheter should 
now all be removed or disconnected
Epidural out? Yes □ No □ Why not?
Drips out or disconnected? Yes □ No □ Why not?
Catheter out? Yes □ No □ Why not?
It is important to start to mobilize rather than lying in bed, therefore you are expected to 
mobilize with the physiotherapist (once a day) and the nursing staff (twice a day). Today 
you should also aim to take a walk on the ward four times
Physiotherapist Yes □ No □  Why not?
Nurses
Morning Yes □ No O Why not?
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Afternoon Yes □ No □ Why not?
Walk on ward 1D 2 0  30  40
Pain relief. Commenced oral painkillers?
Yes O No O Why not?
You should start to think about what things need to be achieved before you can be 
discharged home
Adequate pain control requiring only oral painkillers Yes o No O
Adequate oral intake (food & drink) Yes o No O
Bowels opened Yes o No O
Passing urine Yes o No O
Independent mobility Yes o No O
Ready for discharge? Yes o  No O Why not?
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Post-op Day Four (please tick the relevant boxes once completed)
Drink one bottle of Fortisip three times a day
10am □  2pm □  6pm □
Diet
% Portion Yz
Portion
Full
Portion
If you did not eat, why?
Breakfast
Lunch
Dinner
Your epidural, central line (in your neck), drips in your arms and urinary catheter should 
now all be removed or disconnected
Epidural out? Yes □ No □ Why not?
Drips out or disconnected? Yes □ No □ Why not?
Catheter out? Yes □ No □ Why not?
It is important to start to mobilize rather than lying in bed, therefore you are expected to 
mobilize with the physiotherapist (once a day) and the nursing staff (twice a day). Today 
you should also aim to take a walk on the ward four times
Physiotherapist Yes □  No □  Why not?
Nurses
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Morning Yes □ No □ Why not?
Afternoon Yes □  No □  Why not?
Walk on ward 1D 2 0  30  4 0
Pain relief. Commenced oral painkillers?
Yes O No O Why not?
You should start to think about what things need to be achieved before you can be 
discharged home
Adequate pain control requiring only oral painkillers Yes o No O
Adequate oral intake (food & drink) Yes o No O
Bowels opened Yes o No O
Passing urine Yes o No O
Independent mobility Yes o No O
Ready for discharge? Yes o  No o  Why not?
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Post-op Day Five (please tick the relevant boxes once completed)
Drink one bottle of Fortisip three times a day
10am □  2pm □  6pm □
Diet
% Portion Yz
Portion
Full
Portion
If you did not eat, why?
Breakfast
Lunch
Dinner
Your epidural, central line (in your neck), drips in your arms and urinary catheter should 
now all be removed or disconnected
Epidural out? Yes □  No □
Drips out or disconnected? Yes □  No □
Catheter out? Yes □  No □
Why not? 
Why not? 
Why not?
It is important to start to mobilize rather than lying in bed, therefore you are expected to 
mobilize with the physiotherapist (once a day) and the nursing staff (twice a day). Today 
you should also aim to take a walk on the ward four times
Physiotherapist Yes □  No □  Why not?
Nurses
Morning Yes □ No □ Why not?
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Afternoon Yes □ No □ Why not?
Walk on ward 1D 20  30  40
Pain relief. Commenced oral painkillers?
Yes O No O Why not?
You should start to think about what things need to be achieved before you can be 
discharged home
Adequate pain control requiring only oral painkillers Yes o No O
Adequate oral intake (food & drink) Yes o No O
Bowels opened Yes O No O
Passing urine Yes O No O
Independent mobility Yes O No O
Ready for discharge? Yes o  No o  Why not?
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T h e  bookle t is no w  co m p le te , p le a s e  p lace  it in th e  p re -p a id  e n v e lo p e
provided  an d  post it.
T h a n k  you v e ry  m uch fo r a g re e in g  to partic ipate  in th e  trial.
Useful Contacts
For any questions or concerns regarding your operation or clinical care, please 
contact Laura Spring (Clinical Nurse Specialist in Liver Surgery)
For any questions or concerns regarding the trial, please contact either:
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Appendix 5 EQ-5D Health Questionnaire -  Pre-op (no.1) Best imagmable 
health state
By placing a tick in one box in each group below, please indicate which 
statements best describe your own health state today.
100
Mobility
I have no problems in walking about 
I have some problems in walking about 
I am confined to bed
Self-Care
I have no problems with self-care 
I have some problems washing or dressing myself 
I am unable to wash or dress myself
Pain/Discomfort
I have no pain or discomfort 
I have some moderate pain or discomfort 
I have extreme pain or discomfort
Anxiety/Depression
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed
Usual Activities (eg work ,study, housework, 
family or leisure activities)
I have no problems with performing my usual activities □ 
I have some problems with performing my usual activities □ 
I am unable to perform my usual activities □
Your own health state today
To help people say how good or bad a health state is, we 
have drawn a scale (rather like a thermometer) on which 
the best state you can imagine is marked 100 and the worst 
state you can imagine is marked 0.
We would like you to indicate on this scale how good or bad your own health 
is today, in your opinion. Please do this by drawing a line on the scale above 
on which ever point indicates how good or bad your health state is today.
©  1990 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group.
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0
Worst 
imaginable 
health, state
Appendix:6
No.
Surrey County Hospital
NHS Foundation Trust 
Patient Satisfaction Questionnaire
NHS
I.G ender
ZAge Group
Male □
Female □
1 6 -2 4 □
2 5 -3 4 □
3 5 -4 4 □
4 5 -5 4 □
5 5 -5 4 □
6 5 -7 4 □
75 or over □
3. What surgery did you receive?
Pre-admission c lin ic
4 .Did you feel you were given 
enough information about v/hat va s  
expected o f you In the firs t couple o f 
days after the operation Viras over?
Yes [ J  
Comments:
No □
5.Did you feel you had enough opportunity 
to  ask questions at Pre-admission about 
v/hat v/ould happen a fter y ou r  operati on ?
□  N . OYes
Comments:
A fte r You r Operation
6. Did you feË  yo u r pain v/as v/eli 
controlled?
Y. □
Comnsnts:
No □
7. Did you feel you started to drink at the 
rig h t time?
Yes □ No □
Com rants:
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8. Did you feel that you started to  eat 
a t the ligh t t iim ?
Y e s d  N o d
Coairnenîâ:
9. Did you feel you started to v/alk at 
the right time?
Yes
Cannants:
□ No□
10. Did you feel you v/ere discharged at 
the right time?
Yes CD No CD
Cannants:
11. Did you receive a discharge leaflet 
v/ith a m obile number to call i f  you had 
any questions o r concerns betv/een 
being discharged and your firs t foliov/- 
up appointment?
Yes□ No□
Cannants:
Overaii
1Z Please state any p o s tive  experiences 
you may have had during yo u rtim e a s  a 
patient:
13. Please state i f  any thing did not meet 
you r  eagiectation s v/hile you v/erea 
pa ten t:
14. Any o ther comments
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Appendix: 7
Community Care Questionnaire
This questionnaire along with the quality of life questionnaire 
looks at how you are feeling and to see if you have had any help 
from health care based away from the hospital (eg GP or district 
nurse).
Please fill out the questionnaire on day 14 and 28 after your 
operation (the researcher will tell you exactly which dates).
The researcher will show you how to fill the questionnaire in.
When you have completed your questionnaire, please could you 
return it in the prepaid and preaddressed envelope.
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Community Care Questionnaire- Post-op Day 14 
To be filled in on (date):________
1. Since you were discharged 
from hospital, how many 
times have you:
None 1 2 3 or 4 5 or 
more
Visited your GP surgery
Had a home visit from your GP
Seen a nurse or other health 
professional at your GP surgery
Had a home visit from a nurse or 
other health professional
Visited hospital as an outpatient
Visited hospital A&E or ‘walk in' 
centre
Seen social services staff e.g. care 
manager
Had day treatment in hospital (no 
overnight stay)
Stayed overnight in hospital (number 
of nights)
Bought or received (additional to 
normal) prescription medicines 
(number of items)
Had help at home from social 
services care assistants day days days days
Needed friends or relatives to help 
you at home with normal activities day days days days
Please tell us about any other health 
or social care item or service you 
have received this week.
Community Care Questionnaire- Post-op Day 28 
To be filled in on (date):________
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2. Since the last questionnaire, 
how many times have you:
None 1 2 3 or 4 5 or 
more
Visited your GP surgery
Had a home visit from your GP
Seen a nurse or other health 
professional at your GP surgery
Had a home visit from a nurse or 
other health professional
Visited hospital as an outpatient
Visited hospital A&E or ‘walk in' 
centre
Seen social services staff e.g. care 
manager
Had day treatment in hospital (no 
overnight stay)
Stayed overnight in hospital (number 
of nights)
Bought or received (additional to 
normal) prescription medicines 
(number of items)
Had help at home from social 
services care assistants day days days days
Needed friends or relatives to help 
you at home with normal activities day days days days
Please tell us about any other health 
or social care item or service you 
have received this week.
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Appendix 8 Anaesthetic Protocoi for Liver Resections
Anaesthesia
Propofol 2-4 mg/kg
Fentanyl 2-3 mcg/kg
Cisatracurium 0.15-0.3 mg/kg
Frusemlde 0.5-1 mg/kg
Vit k lOmg in theatre and usual vit k protocol post op (see below). 
Antiemetics
Cyclizine 50 mg
Ondansetron 4mg
Antibiotics
Cefuroxime 1.5g (plus 2 doses post op)
Metronidazole 500mg (plus 2 post op doses)
Epidurai
Inserted atT 6-10
lOmIs 0.125% levobupivicaine before start of surgery
Infusion of 0.1% levobupivicaine and 2mcg/ml fentanyl started in theatre
30 mins after bolus dose at 5-10 mIs/hr.
Lines
Central venous pressure, arterial line and urinary catheter 
Keep patient warm with Bair Hugger (temp >36 0)
Intraoperative drugs
Remifentanil 0.05-0.1 mcg/kg/min
Phenylephrine 0.05-0.20 mcg/kg min. To keep SBP>80 or 
MAP>55mmHg
GTN 1-5 mIs/hr to reduce CVP
60-80% oxygen/air with Sevoflurane (ET MAC 0.5-1.5)
Reversal
Neostigmine 2.5-5.0mg
Glycopyrrolate 0.5-1 mg
Post Op
Clexane 20-40mg sc
Omeprazole 20mg po
Patients admitted to ievel IIICU bed for further management.
Vit K protocoi
Morning post op if:
INR< 1.5 write up Clexane for evening dose 
INR >1.5 but <2.0. Give lOmg vit k and omit Clexane 
INR >2.0 give 1 adullt dose of FFP and omit Clexane 
Protocol continues until INR <1.5
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Appendix 9 Goal Directed Fluid Therapy Protocol
NO
YES
YES
NO
NO
YES
YESTitrate
Inotrope
Is nCO 
<3 L/min
Measure Stroke 
Volume
250 mis Volulyte 
over 2 mins
Is nCO sustained at 
>3L/min
Increase in SV is 
>10% on first cycle or 
15% on further cycles
Repeat SV  
measurement 
every lOmin - 
10% fall in SV
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MATERIAL REDACTED AT REQUEST OF UNIVERSITY
Appendix 11
Table 11.1: Surgical Drain removal - Postoperative day on which surgical drain
was removed
Control Group ERP Group
No drain 9 (20%) 7(15.2%)
Median [IQR] 3 [2-5] 3 [2-4]
POD 1 2 (4.4%) 2 (4.3%)
POD 2 10 (22.2%) 9(19.6%)
POD 3 8(17.8%) 15 (32.6%)
POD 4 7(15.6%) 6(13%)
POD 5 3 (6.7%) 3 (6.5%)
POD 6 1 (2.2%) 1 (2.2%)
POD 7 1 (2.2%) 0
POD 8 1 (2.2%) 0
POD 9 1 (2.2%) 0
POD 10 0 1 (2.2%)
POD 12 0 1 (2.2%)
POD 13 0 1 (2.2%)
POD 14 1 (2.2%) 0
POD 21 1 (2.2%) 0
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Table 11.2: Urinary catheter removal. Postoperative day on which urinary 
catheter was removed
Control Group 
Cumulative %
ERP Group 
Cumulative %
Median [IQR] 5 [4-5] 2 [2-2]
PODO 0 0
POD 1 0 1 (2.2%)
POD 2 0 30 (68.9%)
POD 3 6(13.6%) 6 (82.2%)
POD 4 14 (45.4%) 7 (97.8%)
POD 5 15(79.5%) 1 (100%)
POD 6 7 (95.4%) 0
P0D>7 2(100%) 0
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CVP Removal
Table 11.3: Postoperative day on which CVP line was removed:
Control Group 
Cumulative %
ERP Group 
Cumulative %
Median [IQR] 3 [2-4] 2 [2-3]
PODO 0 0
POD 1 1 (2.3%) 3 (6.7%)
POD 2 12 (29.5%) 23 (57.8%)
POD 3 13 (59%) 9 (77.8%)
POD 4 11 (84%) 9 (97.8%)
POD 5 5 (95.4%) 1 (100%)
POD 6 2(100%) 0
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